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Abstract

Proteinuria is the excess excretion of protein in the urine and is found in a variety of
conditions including renal diseases and neoplastic conditions such as multiple myeloma
(MM). The investigation of proteinuria type through the use of electrophoresis is a
useful and widely used non-invasive diagnostic tool. The aim of this study was to
compare various agarose gel and capillary zone electrophoresis techniques in order to
establish a method choice for the separation of protein in routine laboratories.
Comparisons were made based on urine monoclonal peak quantification and protein
fractions detected. An examination of a capillary zone electrophoresis (CZE) based
method for the identification of monoclonal components was also carried out. Random
urine samples (n = 88) either underwent mechanical concentration prior to analysis by
high resolution (HR) or pi p2 agarose gel electrophoresis; dialysis centrifugation prior to
analysis by CZE or was electrophoresed neat on HR gels. All urines underwent both a
Bence Jones Protein (BJP) gel immunofixation screen (gold standard) and a CZE
immunosubtraction screen. Statistical comparison, using the laboratory’s existing
method of plp2 agarose gel electrophoresis as the standard against which other methods
were compared, showed that best agreement was seen with the HR gel method utilising
neat urine samples. The least association was noted with the CZE method. While very
similar results and medians were noted in all three agarose gel based methods (medians
= 41.75 g/L, 41.2 g/L and 46.6 g/L), the greatest difference in peak quantification was
again seen in the CZE technique with a significantly lower median (median = 29.3 g/L).
BJP immunofixation screening revealed a total of 21 urines containing monoclonal (M)
components. Of these, 16 were evident on CZE and plp2 gel electrophoresis, 18 were
detectable with concentrated urine on HR gel and 17 were detectable with neat urine on
HR gel. CZE did not detect five of the M-component positive urine samples therefore
these samples were incorrectly found to be negative by immunotyping. The CZE
immunosubtraction method also mistyped five of the sixteen M-component positive
samples it did detect. It appears, based on these findings, that HR gel electrophoresis of
neat urine samples followed by BJP immunofixation of any suspected monoclonal
components is the most reliable and least technically demanding technique of those
examined for the investigation of proteinuria.

1.0

Introduction

The term ‘proteinuria’ characterises the excretion of increased protein in urine and this is
attributed to a pathological function of the kidney and the urinary tract. It is one of the
most common non-specific abnormalities which are detected in clinical laboratories in
adults as well as children, it may be temporary or permanent and changes in the amount
or the composition of the specific proteins present can be used as indicators of
pathological processes (1). Proteinuria is not only a well-recognised sign of kidney
disease, but is also an independent risk factor for the progression of renal failure (2) and
so the early diagnosis, differentiation and monitoring of kidney dysfunction is of great
importance in patient care.

Although some of the clinical consequences of proteinuria were described by
Hippocrates, it was not until the seventeenth century that the connection between
nephritic oedema and kidney disease was proposed. The recognition by Richard Bright
of increased urinary protein excretion as a cause of the nephrotic syndrome occurred
nearly a hundred years later. It was Bright who provided the strongest data to link
structural abnormalities of the kidney with proteinuria. Over the ensuing 200 years,
proteinuria was considered more a reflection of alterations in the structural integrity of
the glomerulus or tubules, and hence, the terms glomerular or tubular proteinuria. It has
long been recognized that the persistence of proteinuria was associated with an adverse
outcome, and an increased renal mortality has been reported in these patients (3). It has
also been found that a qualitative change in the urine-protein composition often precedes
increased protein excretion (4). To date, through proteomics, over 1500 different
proteins have been identified in human urine (5).

Historically, proteinuria of greater than 150 mg/24h was regarded as abnormal, however,
it is now appreciated that early renal disease is often characterised by low level
albuminuria (between 30 and 300 mg/24h). This condition is termed microalbuminuria
because the concentration of albumin is below the detection limit of most traditional
assays. Protein or albumin excretion of over 300 mg/24h represents overt proteinuria or
macroalbuminuria (6). Pathological proteinuria can be divided into four categories:
glomerular, tubular, overload and mixed proteinuria. Glomerular proteinuria arises from
an increase in the permeability of the glomerular capillary wall to macromolecules
(particularly albumin) and usually results from glomerular disease. Tubular proteinuria
results from reduced reabsorption of proteins that are normally present in the glomerular
filtrate or from excretion of proteins derived from injured tubular epithelial cells. It is
usually caused by diseases of the tubulointerstitium. Overload proteinuria is due to an
excess of low-molecular weight proteins that are normally reabsorbed by the proximal
tubules, these proteins are most often immunoglobulin light chains (Bence Jones
Proteins) (6). Mixed proteinuria is seen where there is a combination of tubular and
glomerular damage present.

Urine protein electrophoresis (UPE) provides one of the best tools for the general
assessment of the human state of health. It is especially useful for detecting proteins of
restricted mobility associated with myeloma and other lympho-proliferative disorders. In
cases of known monoclonal gammopathy, UPE is an effective tool for monitoring
patient therapy. For centuries, physicians have attempted to use urine for the non
invasive assessment of disease. Today urinalysis, in particular the measurement of
proteinuria, underpins the routine assessment of almost all patients with renal disease.

1.1

Kidney Anatomy

In the adult, the kidneys are about 13cm long, 6cm wide and 4cm thick. They weigh
approximately 150g each yet together they receive about 25% of the resting cardiac
output as supplied by the renal arteries (7). As such, they account for approximately
0,5% of total body mass and under normal physiological conditions generate 150-180
litres of ultra filtrate each day (5). Covering and supporting the kidneys are three layers
of tissue; the innermost layer is a tough fibrous materiel called the renal capsule; the
middle layer is called the adipose capsule and it provides the kidneys with a protective
cushion against impacts and jolts; the outer layer is a sub-serous fascia called the renal
fascia. Each kidney contains approximately one million functional units called nephrons
and each nephron is an independent urine forming unit. (See figure 1 for an illustration
of nephron structure (8)).
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Figure 1. Structure of the Nephron

These nephrons accomplish a number of functions including the initial filtration of
blood, the selective reabsorption back into the blood of filtered substances that are useful
to the body, and the secretion of unwanted substances from the blood into the filtrate.
Two types of Nephrons are recognised, cortical and juxtamedullary with cortical
nephrons being seven times more numerous than juxtamedullary nephrons (7). Each
nephron consists of a tubular component and an associated vascular component. The
tubular component starts with the glomerular capsule (Bowman’s capsule) and includes
the excretory tubules, the Proximal Convoluted Tubule, the Loop of Henle and the Distal
Convoluted Tubule. Each of the excretory tubules leads into a large collecting duct
which transports the resulting renal filtrate (9).

The glomerulus is located in the renal cortex and is the vascular component of the
nephron. It functions to filter low molecular weight plasma waste products into the urine
while restricting the passage of albumin and larger molecules that are necessary for
maintaining normal homeostasis. The glomerular capillary wall is characterised by an
extremely high permeability to water, small solutes and ions, contrasting with a very low
permeability to plasma proteins the size of albumin and larger. The essential components
of the glomerular capillary wall are the fenestrated endothelium, the glomerular
basement membrane and podocytes. The glomerular basement membrane is an
extracellular sheet like structure that serves as a pre-filter (2). Glomerular capillary wall
podocytes contain structures known as foot processes, these interlink with the foot
processes of neighbouring podocytes to form filtration slits which are bridged by
structures known as slit diaphragms. Defects in slit diaphragms have been shown to play
a role in hereditary proteinuric syndromes (10). In fact, the structure of the glomerular
capillary wall has been shown to be altered in most kidney diseases leading to
proteinuria (10, 11).

Congenital absence of one kidney occurs in approximately one in 2400 births, this is
only of significance if renal surgery is contemplated for any reason and the normal
kidney becomes hypertrophic. Another common congenital anomaly, seen in
approximately one in 400 births, is the single ‘horseshoe’ kidney, in which the lower
poles of the potential two kidneys are conjoined; renal function is normal but
occasionally ureteric obstruction may predispose to calculus formation and infection
(12).

1.2

Clinical Aspects

1.2.1

Protein Excretion

The filtration rate of individual proteins through the glomerular membrane depends on
their molecular size, ionic charge and plasma concentration. Cationic proteins pass the
molecular filter easier than anionic ones and proteins with a molecular weight above 80
kDa should not physiologically go through the glomerular barrier (13).

1.2.2

Urine Protein in Health

Since the introduction of sensitive urinary protein assays it is clear that normal urine is
not completely protein free. A normal adult excretes between 10 and 140 mg of protein
per day. The protein content of normal urine is the net result of glomerular filtration,
tubular reabsorption and tubular secretion. Plasma proteins only represent approximately
25 mg/24h of total urinary protein, the remainder being made up of proteins of renal
origin, of which Tamm-Horsfall Protein (THP) is the major contributor (12). THP is
synthesised by cells of the ascending limb of the loop of Henle and distal convoluted
tubules (14). It has been shown that urinary THP exerts a protective role against E. coli
colonisation by competing with glycans carried by membrane glycoproteins of the
urinary tract. (15)
0

1.2.3

Types of Proteinuria

Protein excretion of more than 150 mg/24h is conventionally defined as proteinuria and
is indicative of glomerular or reabsorption dysfunction (5).There are different types of
pathological proteinuria including glomerular, tubular, overflow and mixed proteinuria
which are characterised by different patterns of urinary protein excretion. Albumin,
which has a molecular mass of 69 kDa is the largest protein filtered through the
glomeruli. As albumin is filtered in small quantities, it appears in the proximal renal
tubuli where it is reabsorbed efficiently. When the proximal renal tubules are damaged,
albumin appears in the urine. Therefore, albumin will be present in the urine following
both glomerular and tubular damage (16).

1.2.3.1

Glomerular Proteinuria

The most characteristic feature of glomerular proteinuria is the increasing glomerular
permeability with the increase of urinary excretion of high molecular weight proteins
such as albumin (69 kDa). This is due to damage to the glomerular filtration barrier.
Based on the comparison of the clearance of high molecular weight proteins such as
immunoglobulin G (150 kDa) to that of albumin, the glomerular proteinuria can be
classified as either selective or non selective (13). Protein electrophoresis in the case of
glomerular selective proteinuria will show a pattern of mainly albumin, while
glomerular non-selective proteinuria will have a protein pattern with both albumin and
IgG present (13).

1.2.3.2

Tubular Proteinuria

Tubular proteinuria is defined as tubular damage or an impaired tubular resorptive
capacity with a normal glomerular permeability. It is often seen in patients with tubulo
interstitial diseases. The integrity of tubular function can be assessed by the

11

measurement of low molecular weight proteins such as retinol binding protein, al and
p2 microglobulin that are filtered at the glomerulus, then reabsorbed and catabolised
within the proximal tube (13). Tubular proteinuria often manifests as small quantities of
total urinary protein in the physiological range and is therefore often not investigated in
time for measures required to counter progressive kidney damage to be taken (17, 18).

1.2.3.3

Overflow Proteinuria

This type of proteinuria is often referred to as pre-renal proteinuria. It occurs when the
resorptive capacity of the proximal tubules has been exceeded and low molecular weight
proteins appear in the urine. These proteins are most often immunoglobulin light chains
(in the plasma cell dyscrasias), although lysozyme (in myelomonocytic leukaemia),
myoglobin (in rhabdomyolysis) or haemoglobin (in intravascular haemolysis) may also
be seen (6).

1.2.3.4

Mixed Proteinuria

Mixed proteinuria is characterised by the presence of both tubular and glomerular
proteins and is seen in many types of renal diseases, although the initial onset may be
limited to one cause. Febrile patients also often exhibit proteinuria of the mixed type,
either with or without renal disease (19). Thus, while glomerular permeability may
increase, leading to an increase in albumin excretion in the urine, the increased load on
the resorptive load of the tubules may eventually lead to tubular dysfunction as well
(20), this in turn results in mixed proteinuria.
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1.2.4

Bence Jon es Protein uria

Henry Bence-Jones described the detection of urinary immunoglobulin light chains in
1848. He observed that light chains precipitate when urine is heated to between 40°C
and 60°C, dissolve on further heating to 100°C and then re-precipitate on cooling back
to 40°C to 60°C. These immunoglobulin light chains were named Bence Jones Proteins
(BJP). As false-positive results may occur in the presence of excess polyclonal light
chains, this technique is no longer in clinical use. Urinary light chains are now generally
identified by UPE followed by immunofixation (IFE) (6). Free light chains usually are
either Mr 22,000 monomers or Mr 44,000 dimers and in health should be polyclonally
produced (21). (See figure 2 for immunoglobulin structure (22))

Anligon

Antigen

Figure 2. Immunoglobulin Structure

BJP have been associated with a number of different conditions but are most frequently
seen in multiple myeloma (MM), Waldenstrom’s macroglobulinemia, monoclonal light
chain related amyloidosis and light chain deposition disease. These are relatively rare
conditions; their incidence in western countries varies from 4/100,000/year for MM to
0.9/100,000/year for monoclonal light chain related amyloidosis. BJP may also be
13

associated with lymphomas and chronic lymphocytic leukaemia or may be idiopathic
(benign or of undetermined significance) (23).

MM is a malignant proliferation of plasma cells producing a monoclonal paraprotein.
The disease can present in a range of ways, for example hypercalcemia, hyperviscosity,
renal failure and bone pain or fracture (24). Approximately 50% of patients with MM
excrete monoclonal free light chains in their urine (25, 26). Monoclonal free light chains
are part of immunoglobulins, and are produced by B-cell neoplasias in elevated
amounts. They are excreted by the kidneys as BJPs, and thus can be found in the urine
(27). IFE is recommended as the detection method of choice because of its ability to
demonstrate monoclonality and the absence of heavy chains, it is also considered the
best method to document the disappearance of the monoclonal protein (complete
remission) (23).

Quantification of BJP provides important information as it is strongly correlated with
myeloma tumour cell burden (25). Accordingly, the rate of BJP excretion has been
incorporated in several clinical scoring systems for MM for example the classic
myeloma staging system (28) and more recently, in the criteria for disease response and
progression (25). Thus, the clinical use of BJP quantification in diagnosis, staging,
treatment monitoring and remission monitoring demands analytical methods that are
specific, sensitive and accurate. Several methods are available for the quantification of
BJPs in urine, the most common of which is agarose gel electrophoresis of concentrated
urine followed by densitometric scanning (25). Other methods include peak
quantification of urine capillary zone electrophoresis (CZE) electrophoretograms, high
resolution gel electrophoresis of concentrated urine followed by densitometric scanning
or high resolution gel electrophoresis of neat urine followed by densitometric scanning.
All of these methods carry difficulties including a reliance on urinary protein
measurement to facilitate deduction of monoclonal peak quantification. The ability of
most total urine protein quantification methods to measure light chains is uncertain and
so final urine BJP estimations may be inaccurate (25). In the case of techniques which
require concentration of the urine samples, it is known that proteins may be lost during
14

the concentration process, depending on their size and charge and thus lead to inaccurate
peak quantification (25, 29).

These variations are illustrated in the results of analyses of four different BJP-containing
samples by approximately 170 different laboratories in the United Kingdom External
Quality Assessment program. These analyses produced coefficients of variation in BJP
measurements of 30%, 65%, 68% and 76% respectively (25). Advancement in the
treatment of MM is often based on multi-centre clinical studies (25), therefore method
dependant variations in quantification of M-components in plasma and BJPs in urine is a
major challenge which needs to be addressed.

1.2.5

Renal Disease

Many renal diseases specifically affect one part of the kidney, for example there are a
range of conditions primarily affecting the glomeruli. Glomerulonephritis which is often
of immunological origin may manifest itself as decreases in glomerular filtration rate or
changes in glomerular permeability which can lead to proteinuria. The glomerular
barrier is affected in most inherited and acquired glomerular diseases characterised by
proteinuria. A considerable number of conditions both inherited and acquired, limited to
the kidneys and having extrarenal manifestations, can cause disorders of renal tubular
function. For example, chronic renal failure (CRT) in children is caused by congenital
malformations in more than 50% of cases while diabetes, hypertension and
glomerulonephritis are the major causes of CRF in adults (30). The kidneys may be
affected by infection, tumours,

infiltrative and degenerative disorders, shock,

hypertension, connective tissue diseases and diabetes to name a few (12).

Regardless of the cause of proteinuria, there is increasing evidence from a large number
of studies supporting the theory of the harmful secondary effects of this protein flow on
the kidney. Thus, a strong relationship between the magnitude of proteinuria and the rate
of decline of renal function has been reported to exist in most glomerular disorders
15

including

focal

segmental

glomerulosclerosis,

mesangiocapillary glomerulonephritis,

membranous

nephropathy,

immunoglobulin A nephropathy,

Henoch-

Schonlein purpura, diabetic nephropathy and systemic lupus erythematosus (2, 3). A
large screening study of 40,856 members of the population of Groningen in the
Netherlands showed that the degree of proteinuria was not only predictive of
development of renal failure but also of later development of cardiovascular disease
(30). Another recent study showed that filtered proteins are toxic to the tubules through
re-absorption overload. Proximal tubular overloading with albumin and other proteins
stimulates tubular cells to produce inflammatory and vasoactive substances such as
monocyte chemo-attractant protein-1 (MCP-1) and endothelins which are capable of
inducing tubulointerstitial

inflammation

and

fibrosis thus contributing to the

deterioration in renal function and progression of disease (17). In the Modification of
Diet in Renal Disease (MDRD) study, which was designed primarily to evaluate dietary
protein restriction and blood pressure control in 840 patients with renal disease, it was
demonstrated that the degree of proteinuria significantly predicts the decline in
glomerular filtration rate (31). This study also showed that the benefit of aggressive
blood pressure control on the progression of non-diabetic renal disease was greater in
patients with higher urine protein excretion at onset of therapy. No benefit of aggressive
blood pressure reduction was seen in patients with less than 1 g per day urine protein
excretion (31).

In 1998, a Finnish research group identified the gene mutated in congenital nephrotic
syndrome of the Finnish type, a rare autosomal recessive disease characterised by
massive proteinuria at birth and the absence of a slit diaphragm. The disease gene was
shown to encode a protein called Nephrin that is located in the slit diaphragm. More
recently, a few other proteins, both intra- and extra- cellular, have been shown to form
part of a protein complex that contributes to the slit diaphragm structure. Mutations in
any one of these proteins leads to nephrotic syndrome (2). The majority of patients with
Nephrotic syndrome face the prospect of high level chronic protein loss. In adults two of
the most common causes, diabetic nephropathy and membranous nephropathy create
major challenges in terms of therapy with the continuing state of heavy proteinuria
16

posing several risks to the patient. Three main approaches have been adopted in order to
address this: dietary protein restriction, non-steroidal anti-inflammatory drugs and
angiotensin converting enzyme (ACE) inhibition (32).

The presence of microalbuminuria (30-300 mg/24h) in patients with type 1 diabetes has
been found to correlate with progressive renal damage as well as increased
cardiovascular morbidity and mortality in both type 1 and type 2 diabetics (1).
Therefore, it is now widely accepted that the regular quantification of urine albumin is
part of the ongoing management of diabetes as an adjunct to the haemoglobin Aic
measurement and clinical assessment of eyes, feet, peripheral circulation and nervous
system. Expert groups have defined the stages in progression of diabetic nephropathy on
the basis of urine albumin excretion (20). There is evidence to indicate that regular
screening of patients with diabetes will assist in reducing the rate of onset of renal
complications (20).

It is clear therefore, that proteinuria as a presenting feature is not specific to any one
renal disease. However, in combination with histological and clinical data, the analysis
of urinary proteins in patients with renal disease, has been demonstrated to be a valuable
non-invasive diagnostic tool (13).

1.2.6

Other Causes of Protein uria
1.2.6.1

Age

Age is recognised as a risk factor for renal disease. Studies have shown that people over
the age 69 years are at a significantly increased risk of proteinuria. A cross-sectional
study carried out by Joshi et al. has shown that as many as 9.6% of the elderly in
Singapore may have proteinuria. As is the case in Ireland, the population above 65 years
of age is expected to increase significantly in many countries in the coming years and as
a pandemic increase in end-stage renal disease has been predicted in many regions of the
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world, screening and prevention of proteinuria may be of benefit as part of a renal
screening programs for the elderly (33).

In neonates, albumin excretion tends to be higher than in older children and adults, this
has been attributed to the greater permeability of the neonatal glomerulus (12).
Proteinuria in a single urine specimen is relatively common in children with a reported
prevalence of 1-10% and of probable little significance, persistent proteinuria however is
much less common with one American study of nearly 9000 school children reporting
proteinuria in 1 out of every 4 samples in 10.7% of children but proteinuria in all 4
samples as only 0.1% (34).

1.2.6.2

Orthostatic Proteinuria

In both adults and children ambulatory urine protein excretion is higher than in
overnight excretion, with two to ten fold differences being reported for urinary albumin
(12). Postural or orthostatic proteinuria is common in both children and adults. It is
defined as non-pathological proteinuria usually occurring between the ages of 10 and 20,
and manifested when the individual stands erect but disappears when the person lies
down (35). In this disorder the 24 hour urine protein excretion is usually less than Ig,
although higher values have been reported. A number of long-term follow up studies
strongly suggest that this is a benign condition with excellent prognosis (34). Orthostatic
proteinuria should be excluded in diagnosis of pathological proteinuria by repeat
measurement on a first morning specimen if the initial findings of proteinuria were
obtained in a random sample (34). The medical management of orthostatic proteinuria in
an otherwise healthy patient tends to be conservative with annual assessment of
proteinuria and renal function (12).
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1.2.6.3

Exercise Induced Proteinuria

Over a century ago, exercise induced proteinuria was noticed in soldiers after marching
and drills. Urinary protein has been found to be grossly elevated in marathon runners
post 26 mile races, with up to 100-fold increases observed (12). Proteinuria has also
been found in high altitude mountain trekkers, with 49% of subjects in one study
showing protein in their urine when samples were taken post-trek. This was proposed to
have been due to the combination of exhaustive exercise and hypoxia due to altitude
(36).
The pattern of exercise induced proteinuria is generally glomerular, although mixed
glomerular and tubular proteinuria has also been described which usually persists for
over 3 hours after exercise. The reason for this exercise induced proteinuria is unclear
but may possibly be due to renal ischemia (12). Excretion has been found to be greatest
in the first 20 to 30 minutes after stopping exercise but may be found up to 24 hours
after cessation of exercise (19).

1.2.6.4

Proteinuria in Pregnancy

Proteinuria is a common finding in pregnancy and usually attributable to physiological
changes that concurrently reduce serum albumin by 5 to 10 g/L. Urinary loss rarely
exceeds 0.4 g/24h but nephrotic levels occur in up to 0.025% of all pregnancies (37).
Proteinuria in pregnancy is often transient and generally glomerular in origin whereas
tubular proteinuria, when present, is more likely to persist postpartum (19). Studies have
also shown that proteinuria in pregnancy indicates an increased likelihood, and thus
predicts, longer-lasting hypertension post-delivery (38). Pre-eclampsia which accounts
for most hypertensive disorders of pregnancy is diagnosed by the presence of
hypertension after 20 weeks of gestation and proteinuria, the diagnosis of pre-eclampsia
in the absence of proteinuria is said to be questionable (39).
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1.2.6.5

Post Transplantation Proteinuria

Proteinuria developing in the post-transplantation period frequently results from
transplant glomerulopathy, chronic rejection, renal vein thrombosis, reflex nephropathy
and glomerulonephritis. It has been reported that proteinuria in the early post
transplantation period commonly recedes and that neither the concentration, the type nor
the duration of the proteinuria is of significance (40). It has also been shown however,
that after the initial post-transplant period, patients with heavy glomerular proteinuria
have poor allograft outcomes (41).

1.2.7

Treatment of Proteinuria

The prevention of the progression of renal disease is of particular concern in a country
with an aging population such as Ireland. The number of elderly persons in the general
population is progressively increasing worldwide and Ireland is no exception to this
trend. According to recent data from the Republic of Ireland Central Statistics Office
(CSO), there were 436,001 persons aged 65 or greater in Ireland in 2002 (total
population of 3,917,203). Data published in 2005 by the CSO predict that the elderly
population (aged >65 years) will double in Ireland between the years 1996 and 2031,
increasing from the current rate of approximately 414,000 to around 850,000. Taking
this in conjunction with the fact that end stage renal disease (ESRD) increases with
advancing age, the need for renal replacement therapy in the elderly has expanded
dramatically. The number of dialysis patients older than 65 years has more than doubled
within the past 10 years in the United States. In Europe, patients older than 60 years now
account for more than 50% of the population requiring renal replacement therapy (42).

Therapeutic intervention can delay progression of renal disease and is most significant in
patients with significant proteinuria (43). Prospective therapeutic intervention studies to
decrease proteinuria have shown a diminished rate of progression of kidney disease
when compared with untreated patients (2). Treatment of proteinuria has focussed on
blocking the renin-angiotensin system (RAS) and usually starts with an angiotensin
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converting enzyme (ACE) inhibitor; in adults the addition of an angiotensin II (ATII)
receptor antagonist seems to give further benefits (30). See figure 3 for mechanism of
action (44).

Angiolensinogen

Q.g. cnyrrasc,
catnopsin G

t

Honin

Angiotensin I
ACL inhoilof o.g. caplopril
-------- ACL

—

Angiotensin II

\

AngioLonsm II rocdptor
innibitof. Q.g. losartan

T Giomctulat nyporlcnsion
"t Inflammalon

4" r ibfOSis
T Giomciular porrrcabilily

ACL = aigiolonsin convorlng cn^yrrc

Figure 3: Mechanism of action of ACE and Angiotensin II Receptor Inhibitors

Several large controlled therapeutic intervention studies have confirmed that proteinuria
is a strong and independent predictor of renal failure in both diabetic and non-diabetic
disease (2). In a two year trial the ACE inhibitor captopril was shown to significantly
reduce the progression from micro-albuminuria to overt proteinuria in type 1 diabetics
without hypertension (45)
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A large ongoing prospective study in children called the ESCAPE trial, in which 70% of
patients have CRF due to renal hypodysplasia, has found that proteinuria was reduced on
average by 50% when patients were treated with the ACE inhibitor ramipril (30).
Another trial entitled the ACE inhibition in Progressive Renal Insufficiency (AIPRI)
trial involved 583 patients suffering from a range of renal diseases and tested the
efficacy of benazepril on the progression of renal failure. This study found a risk
reduction in all treated proteinuric patients which was dependant on the degree of
proteinuria present at the start of the trial (46).

Both ACE and ATIl receptor antagonists have been shown to be effective in reducing
proteinuria and renal failure progression rate. For this reason it has been recommended
that patients with normal blood pressure and renal disease with proteinuria exceeding 0.5
g/24h should be prescribed ACE inhibitors and/or ATll receptor antagonists for their
positive effects in reducing proteinuria (2). Other possible beneficial therapeutic
interventions such as lipid lowering and diminished protein intake need to be looked at
in further controlled trials (2).

1.3

Laboratory Assessment of Proteinuria

The measurement of total protein alone, it has been accepted, is often of limited clinical
value, especially when small changes are of pathological significance and when the
classification of proteinuria type is required (18, 20).The identification of proteinuria
type is a useful tool in the identification of the cause of the renal disorder. Many
different diagnostic approaches exist for the investigation of proteinuria type in the
clinical laboratory and these techniques include a variety of immunologic and
electrophoretic methods.
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1.3.1

Sample Type

Until recently, 24h urine collections have been the standard of practice for assessing and
quantitation of proteinuria in patients with renal disease, however many studies have
been conducted which indicate that in most cases a spot urine protein/creatinine ratio is
sufficient to screen for and monitor proteinuria (47). In order to assess proteinuria in a
spot sample the urine protein concentration may be looked at in conjunction with the
creatinine concentration as a ratio. The excretion of creatinine is fairly constant in an
individual patient and this represents a method of standardising protein excretion in a
single void specimen to correct for variation in hydration (43). Timed urine collections
are recommended when knowledge of the absolute level of proteinuria is required (48).
Although recommended by the College of American Pathologists, 24 hour urine
collections are cumbersome and erratic. They also carry the drawback that BJPs are
particularly prone to bacterial degradation and so for the purpose of BJP investigation,
the use of a second morning void has been recommended by other groups (23, 49).

1.3.2

Urine Protein Estimation

For the purpose of screening, therapeutic monitoring and routine investigation of
patients for proteinuria in both hospitals and private practice urine test strips are often
employed. These strips are most sensitive to albumin and generally involve a cellulose
test pad impregnated with tetrabromphenol blue buffered to a pH of about 3. The
reaction is based on the ‘protein error of indicators’, a phenomenon in which certain
chemical indicators demonstrate one colour in the presence of protein and another in its
absence (50). The lower limit of sensitivity for urine dipstick testing is about 250 mg/L;
therefore this method cannot detect microalbuminuria (6). However, as this test method
does not adequately detect proteins other than albumin, a negative result does not
exclude proteinuria and further testing may be warranted if proteinuria is clinically
suspected. This may be an issue in the case of proteinuria in tubulointerstitial diseases
and excretion of monoclonal free light chains in lympho-proliferative processes which
are often missed by test strip analysis (2, 27).
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Previous studies have revealed that total protein concentrations in urine vary, depending
on the measurement method used. In general, measurement of protein content in samples
precipitated with trichloroacetic acid (TCA) is accurate because TCA precipitation
removes urinary non-protein molecules that interfere with protein assays (51). Post
precipitation the sample may be analysed by techniques such as the Biuret method or the
Ponceau S method. This however, is a two step, time-consuming, laborious process that
is not practical for use in most routine clinical laboratories which require accurate,
precise and reproducible results in the minimum of time. Some of the automated urinary
protein measurement techniques currently in use include the benzethonium chloride, the
pyrogallol red, the coomassie blue or the pyrocatechol violet dye methods (52).

A study by Dube et al. outlined the occurrence of discrepancies between urinary protein
determinations by automated analysers and the expected agarose electrophoresis band
intensities. They suggested that reference ranges for urinary protein should vary
depending on the particular methodology used and that automated assays are inadequate
for the measurement of urinary protein in the normal range. They do however suggest
that these assays are probably adequate for measurement of urinary proteins over 0.5 g/L
(52). A particular cause of discrepancies in urinary protein measurement techniques is
the presence of BJP in the sample. This is highlighted by the United Kingdom National
External Quality Assessment program for measurement of BJPs, which found a 31-53%
variation among the total urine protein concentration in the presence of BJP with
different methods (25).

1.3.3

Immunoassay

Immunoassays utilising various detection techniques such as nephelometry, turbidimetry
or colorimetry are often employed for the quantification of individual urine proteins and
provide accurate and sensitive measurements of these proteins (13). One of the most
commonly measured urinary proteins for assessment of tubular damage is almicroglobulin due to its high plasma concentrations, its sensitivity in detecting tubular
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dysfunction and its excellent stability in urine. It has been shown that (32-microglobulin
on the other hand is rapidly degraded in urine at pH 6 or less (13). Useful urinary
proteins to immunoassay in the assessment of glomerular damage are albumin,
transferrin or immunoglobulin G. Combined with serum transferrin and IgG; the protein
selectivity index can be calculated. This is the ratio of IgG clearance to that of
transferrin clearance and is a good marker of the glomerular capillary wall porosity (17).

1.3.4

Mechanical Urine Concentration

Due to the low levels of protein in urine many urine protein analysis techniques require a
mechanical concentration step, using disposable concentrators prior to testing. This is in
order to ensure the techniques to be used for protein separation will detect the protein
present. Many problems have been reported with this concentration step. One
documented problem, described failure of the protein present to appear on the gel due to
the increased amount of interfering sediment in the concentrated sample which inhibited
its ability to wick to the end of its applicator and appear on the gel (53). It is now
recommended that users of concentrated urines ensure that sample wicks to the end of
the applicator before placing it on the gel. Mechanical urine concentration has been
found to cause the loss of low molecular weight proteins such as BJP, cause the
appearance of ladder patterns on electrophoretic gels and cause prozone effects (26). It is
thought that concentration is particularly troublesome with samples containing BJP
because of its variable tendency to polymerise and aggregate (54). One group reported
the occurrence of a missed BJP due to inadequate concentration of the sample prior to
IFE highlighting the importance of performing Bence Jones IFE in conjunction with
UPE on all samples from patients under clinical suspicion (29).
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1.3.5

Electrophoresis

The term electrophoresis refers to the migration of charged particles in an electrical
field. The success of electrophoresis in separating serum and urine proteins into
clinically useful fractions results from the heterogeneity of the charges of these
molecules (55). Electrophoretic techniques provide a qualitative assessment of the
pattern of urinary proteins present that are not easily available with an individual assay.
Interpretation of electrophoretic gels and capillary zone electrophoretograms is
performed visually by an experienced user. Utilising densitometric scanning a semiquantitative value can be given to individual protein fractions.

1.3.5.1

Capillary Zone Electrophoresis (CZE)

The technique of CZE involves the application of high voltage to a thin fused-silica tube
causing electro-osmotic flow (EOF) within the capillary (See Figure 4 (56)), this allows
for the rapid and efficient separation of ionised molecules or complexes. Protein analysis
is usually performed in free solution with the use of highly basic buffers to minimise
interactions with capillary walls. Direct quantification is obtained in the low ultraviolet
(UV) range at the cathodic end of the capillary (57) which is connected to a computer
system which records the separated components detected (58).

Cathode

Anode

Figure 4; Capillary Electrophoresis System
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A complication of urine protein analysis by CZE is the presence of other low molecular
weight compounds that absorb at the same wavelength (200-214 nm) which necessitates
sample pre-treatment procedures before capillary analysis (59). Possibly due to the
perception of the need for increased technical skills, CZE has not yet been widely
accepted as a routine method in clinical laboratories. This was evident in a survey of
clinical laboratories between 2001 and 2004 which showed that there was no increase in
the 1.7% of laboratories utilising CZE for serum protein electrophoresis in that
timeframe (59). In spite of this, CE has many attractive features including the ability to
separate a range of analytes, speed, the requirement for a very small sample size, and
reproducibility (59). The automation of the instrument has allowed high throughput
which is necessary most routine clinical laboratories. From a separations perspective,
proteins pose unique challenges and opportunities. Their net charge may be positive,
negative or neutral depending on whether they are below, above or at their isoelectric pH
respectively, so their electrophoretic mobility is dependant primarily on the pH of the
separation medium used, their size and their tertiary structure (59). The buffer used for
CZE will generally be a one-component buffer such as borate buffer (58).

1.3.5.2

High Resolution (HR) Gel electrophoresis

It is claimed that HR gel electrophoresis allows for the detection of more subtle
monoclonal gammopathies than standard agarose gels (55). HR gel electrophoresis of
urine samples may be carried out using either concentrated or neat urine samples,
depending on the degree of sensitivity required, and separates urine proteins according
to their charge (14). Separation is carried out on alkaline buffered (pH 8.6) agarose gels
followed by staining with protein stains such as acid violet or amido black (60).
According to the guidelines published by Keren et al., urine electrophoresis of high
resolution is indicated for all patients suspected of having a plasma cell dyscrasia such
as MM, Waldenstrom’s macroglobulinemia or amyloidosis (61).
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1.3.5.3

Agarose Gel Electrophoresis

This technique generally involves a mechanical urine concentration step followed by
manual application of the concentrated sample to an device which in turn applies it to
the alkaline buffered gel (pH 8.5). Proteins are separated into five or six fractions in an
electrical field similar to HR gel electrophoresis, the level of sensitivity obtained
however is said not to be as high (55).

1.3.6

BJP Identification

At present, both pre-analytical and analytical methods for assessing BJP are poorly
standardised even though widely used in clinical laboratories (54). Protein reference labs
strive to measure 0.01 g/L BJP in urine (23) and it is estimated that 0.01 g/L BJP equates
to approximately 100,000 tumour cells which is a level indicative of minimal residual
disease. For diagnosis, concentrations of BJP > 0.1 g/L are likely to indicate B-cell
malignancy.

Currently,

many clinical

haematologists are recommending

more

aggressive chemotherapies and so the ability to intensify BJP bands and monitor low
levels of BJP is critical (62). It is recommended that any method used for BJP
identification should have the ability to show if any light chains present are free and
monoclonal. IFE using specific antisera for free light chains combines an electrophoretic
step to verify the molecular homogeneity of the protein with immunologic typing. Visual
interpretation must be carried out with care, ensuring that light chain ladder patterns are
not mistaken for BJP (23). The light chain ladder pattern has been well described and is
a consequence of the excretion of polyclonal light chains in individuals with impaired
tubular reabsorption (26, 63).

CZE immunosubtraction of BJP has yet to be developed with free

k

and X, antisera. At

present, a screen which lacks the free light chain component is available which, if
positive, requires further gel IFE of the sample for BJP (64).
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It is recommended by the American College of Pathologists that electrophoresis and IFE
should be carried out on a concentrated urine sample. The detected BJP peak should then
be scanned densitometrically, and using the urine total protein value and the area under
the curve, the concentration of BJP present is deduced (61). This procedure however,
has some drawbacks including the inaccuracy of the methods in use to detect total urine
protein and the issue that different proteins can have different affinities for the dyes used
to stain electrophoretic gels. These drawbacks can lead to a lack of linearity of the
densitometric response observed and therefore, it is suggested that follow up of patients
should be performed in the same laboratory in order to minimise analytical variability
(23).

At present, there is no commercially available internal quality control (QC) material
available that contains BJP, if available this control material could be used by all clinical
laboratories that analyse urine for BJP.

An external quality assurance programme

operates from Sheffield in the United Kingdom which a urine sample for BJP is
distributed every eight weeks for analysis for return within a three week period (65).

1.3.7

Sample Pre-treatment

Due to the presence of a variety of interfering substances in urine a sample preparation
step is required prior to some electrophoretic techniques. CZE is particularly prone to
interference due to its detection wavelength of between 200 and 214 nm (66), at which
many low molecular weight substances absorb. One commercially available urine CZE
kit produced by Sebia recommends dialysis pre-treatment of urine sample prior to
analysis (67). This serves to remove interfering substances such as salts from the sample
which cause significant noise and may produce false monoclonal peaks (54). Removal of
these salts is also necessary to reduce the possibility of heat generation and high currents
which they are known to cause in air bubbles and current breakdown in CZE instruments
(68).
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1.4

The Future - Proteomics?

Proteomics is the study of protein expression in an organism (69), the goal of which is to
discover proteins that are medically relevant. Comparison of protein patterns in
biological fluids between healthy individuals and patients with disease is increasingly
being used both to discover biological markers of disease (biomarkers) and to identify
biochemical processes important in disease pathogenesis. Although currently available
tests for urine proteins measure either the total level of urine protein or the presence of a
single protein species such as albumin, more complex techniques allow for the
simultaneous examination of urinary protein patterns and their correlation with
individual diagnoses, response to treatment or prognosis. As stated previously, to date
over 1500 different proteins have been identified in human urine (5).

Although not yet in routine use, through proteomics, urine may be a suitable material for
the diagnosis of diseases that are related to the kidney and urologic tract. Urine proteome
analysis for disease marker identification has already been applied to prostate cancer,
renal cell carcinoma, bladder cancer, urothelial carcinoma, renal Fanconi syndrome,
transitional cell carcinoma, type 1 diabetes and acute rejection of renal allograft. Several
potential biomarkers for these diseases have been reported. It has been shown that
biomarker candidates exist in urine which have the ability to distinguish between renal
transplant patients with no rejection and those with acute rejection. These biomarker
candidates may be the basis for developing a non-invasive method of diagnosing acute
rejection without the morbidity and mortality associated with needle biopsy, and is an
area of considerable research at present (69) (70). To date most studies of urine protein
biomarkers have employed two-dimensional gel electrophoresis and so, the identified
proteins were limited to soluble and abundant protein classes. In the future high
throughput and quantitative mass spectrometry may be combined with other techniques
to allow for the identification of many more disease biomarkers which, it is predicted,
will contribute to the diagnosis and classification of disease (5).
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1.5

Objectives

This

project

aims

to

compare

four

commercially

available

urinary

protein

electrophoretic techniques, including the relatively new technique of urine protein CZE,
six fraction pi(32 gel electrophoresis and high resolution gel electrophoresis using both
concentrated and neat urine. Comparisons will be made based on the various techniques’
ability to separate urinary proteins and to detect and quantify any monoclonal
component present.
This study also aims to compare a CZE immunosubtraction method with the traditional
gold standard method of BJP gel IFE for urinary monoclonal component classification.
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2.0

Materials

2.1

Samples

Random urine samples obtained from human subjects were collected into plain universal
containers. Samples stored at less than -70°C were stable for at least one month or for
one week at 2-8°C.
Innova UlOl Ultra low temperature freezer was supplied by New Brunswick Scientific
(Edison, N.J.)
Normal control serum (product number 4785) was purchased from Sebia (Evry Cedex,
France). The normal control serum was in the stabilised lyophilised form. It was stored
at 4°C prior to use and was stable until the expiration date stated on the vial.
Liquicheck, urine chemistry control material for urine micro protein (MTP), was
obtained from Bio-Rad Laboratories (Irvine, CA), was stored at 4°C prior to use and was
stable until the expiration date stated on the vial.

2.2

Sample Pre-treatment

Eppendorf 5810 bench top centrifuge was supplied by Eppendorf (Hamburg, Germany).

2.2.1

Urine Concentration

Urine concentration chambers were purchased from Sartorius Stedium Biotech GmbH
(Goettingen, Germany) and were stored at room temperature until used or the expiration
date indicated.
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2.2.2

Urine Dialysis and Concentration

Vivaspin 6ml concentrators were purchased from Sartorius Stedium Biotech GmbH
(Goettingen, Germany) and were stored at room temperature until used or until the
expiration date indicated.
Sebia Capillarys dialysis systems (Product number 9200) were purchased from Sebia
(Evry Cedex, France) and were stored at room temperature until used or until the
expiration date indicated.

2.3

Urine Protein Estimation

MTP kits were purchased from Beckman Coulter Inc. (Fullerton, CA) This reagent kit
was stable at when stored at 4°C or until the expiration date indicated.
Synchron LX20 automated clinical chemistry analyser was supplied by Beckman
Coulter Inc. (Fullerton, CA).

2.4

Urine Electrophoresis

2.4.1

Capillarys Urine

Capillarys Urine kit (Product number 2012), Capillarys Protein (E) kit (Product number
2003) and green dilution segments (Product number 2081) were all purchased from
Sebia (Evry Cedex, France) and were stable at room temperature or until the expiration
date indicated.
Capillarys 2 automated capillary electrophoresis instrument was supplied by Sebia (Evry
Cedex, France).
Phoresis software package for use in conjunction with Capillarys 2 was supplied by
Sebia (Evry Cedex, France).
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2.4.2

15 plpl Agarose Gel Electrophoresis

Hydragel 15 plpl kits (Product number 4121) containing agarose gels, buffered strips
and amido black stain, applicators and filter paper were purchased from Sebia (Evry
Cedex, France). Hydrasys wash and destaining solution were also purchased from Sebia
(Evry Cedex, France). These materials were stable at room temperature or until the
expiration date indicated.
Hydrasys electrophoresis platform and wet storage chamber were supplied by Sebia
(Evry Cedex, France).

2.4.3

High Resolution (HR) Gel Electrophoresis

Hydragel 15 high resolution kits (Product number 4122) containing agarose gels,
buffered strips, acid violet stain, applicators and filter paper were purchased from Sebia
(Evry Cedex, France). Hydrasys wash and destaining solution were also purchased from
Sebia (Evry Cedex, France). These materials were stable at room temperature or until
the expiration date indicated.
Hydrasys electrophoresis platform and wet storage chamber were supplied by Sebia
(Evry Cedex, France).

2.5

Densitometry

Hyrys Densitometric Scanner was obtained from Sebia (Evry Cedex, France).
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2.6

BJP Investigations

2.6.1

Bence Jones Immunofixation

Hydragel 4 Bence Jones kits (Product number 4824) containing agarose gels, buffered
strips, acid violet stain, applicators filter paper combs and filter paper were purchased
from Sebia (Evry Cedex, France). These materials were stable at 4°C or until the
expiration date indicated.
Antisera GAM-K-L kit (Product number 4835), which contains anti-y, a and p
combined, anti-K (free and bound), anti->^ (free and bound) and fixative solution, was
purchased from Sebia (Evry Cedex, France). These antisera were stable at 4°C or until
the expiration date indicated.
Antisera Kf-Lf kit (Product number 4836), containing anti-K (free) and anti-y (free), was
purchased from Sebia (Evry Cedex, France). These antisera were stable at 4°C or until
the expiration date indicated.
Hydrasys electrophoresis platform, wet storage chamber and antisera standard mask
were supplied by Sebia (Evry Cedex, France).

2.6.2

Capillarys Immunotyping

Capillarys Immunotyping kit (Product number 2100) consisting of antisera segments
containing, fixative, anti-y, anti-a, anti-p, anti-K and anti->^ were purchased from Sebia
(Evry Cedex, France). These reagents were stable at 4°C or until the expiration date
indicated.
Capillarys Protein (E) 6 kit (Product Number 2003) was purchased from Sebia (Evry
Cedex, France) and was stable at room temperature or until the expiration date indicated.
Capillarys 2 automated capillary electrophoresis instrument was supplied by Sebia (Evry
Cedex, France).
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3.0

Methods

3.1

Sample Collection

With the approval of the ethics committee of the Mid-Western Regional Hospital,
Limerick (MWRH), a minimum of 10ml of urine was collected into a sterile universal
container with no added preservative from 88 volunteers attending renal and
haematology out patient clinics of the MWRH. All participants were furnished with a
patient information sheet, outlining the purpose of the research and what was required of
them, before signed consent was obtained (See Appendix A for consent form and patient
information sheet). Immediately after collection, samples were labelled with patients
name and date of birth in the presence of the patient.
*

In the laboratory, urine samples were allocated a specimen identification number
(001, 002, etc.) and transferred to 4.9 ml Sarstedt neutral tubes.

*

Specimen tubes were centrifuged at 3300 rpm for 10 minutes in an Eppendorf
bench centrifuge.

*

The resulting supernatant was removed and transferred to a clean, appropriately
labelled, 4.9 ml Sarstedt neutral tube. The remaining sediment was discarded.

*

After measurement of MTP levels, the urine supernatant was stored at -80°C
until required for further analysis.

3.2

Urine Protein Estimation

Urine protein estimation was carried out using the Beckman MTP assay designed for the
Synchron LX20 Instrument. MTP reagent was used to determine protein concentration
by a timed endpoint method. Protein in the sample reacted with the pyrogallol red and
molybdate to form a purple colour complex which has a maximum absorbance at 600
nm. The change in absorbance at 600 nm was directly proportional to the rate of
complex formation which in turn is proportional to the protein concentration in the
sample (71). Two levels of Randox urinalysis QC material were analysed with each
batch of patient samples.
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As is the policy of the clinical chemistry laboratory, Mid-Western Regional Hospital,
only urine samples with micro total protein values of greater than or equal to 0.15 g/L
were further processed for UPE. See appendix B for assay procedure and performance
data.

3.3

Sample Pre-treatment

Prior to electrophoretic separation, sample pre-treatment was required due to the
possible presence of interfering substances and the insufficient sensitivity of some of the
electrophoretic techniques.
3.3.1

Urine Concentration

Samples were concentrated to a protein value of approximately 20 g/L using Vivapore
10/20 concentrators. 10 ml of urine was placed in each concentration chamber until the
high capacity absorbent membrane had reduced the volume to the required pre
calculated concentration factor, as calculated using the following formula:

20/Urine Protein (g/l) = Required Concentration Factor

3.3.2

Urine Dialysis and Concentration

Two different systems were used for the urine dialysis and concentration step prior to
analysis by CZE.
3.3.2.1

Dialysis and Concentration by Vivaspin 6ml Concentrators

Concentration and dialysis were carried out using Vivaspin 6ml concentrators and
working dialysis buffer contained in Capillarys Urine kit (See appendix B for
procedure). The procedure resulted in the production of a dialysed urine sample of
approximately 100 pi volume which was suitable for analysis by CZE.
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3.3.2.2

Dialysis and Concentration by Sebia 20ml Dialysis Systems

Concentration and dialysis were carried out using Sebia Dialysis 20 ml System and
working dialysis buffer contained in Capillarys Urine kit. The procedure (See appendix
B for procedure) resulted in the production of a dialysed urine sample of approximately
500 pi volume which was suitable for analysis by CZE.

3.4

Urine Electrophoresis

3.4.1

Capillarys Urine

Following the pre-analytical treatment of urine samples by the methods described above
in section 3.3.2.1 or 3.3.2.2 with the Capillarys Urine kit, urine protein electrophoretic
separation of samples was carried out on the Capillarys 2 system.
Liquid flow electrophoresis simultaneously separated urinary protein in alkaline buffer
(pH 9.9) through eight silica lined capillaries. Charged molecules are separated based on
their electrophoretic mobility in alkaline buffer. Separation was carried out under high
voltage and was controlled by the Peltier effect. The direct detection of proteins was
made at 200 nm at the cathodic end of the capillaries resulting in an electrophoretic
profile (67). Sebia normal serum control was analysed by each of the eight capillaries
prior to sample processing. (See appendix B for full description of procedure and
performance data).

3.4.2

HR Gel Electrophoresis

Hydragel HR protein electrophoresis kits were designed for the multi-fractionation of
proteins in biological fluids such as urine and cerebrospinal fluid. Electrophoresis was
carried out on alkaline buffered (pH 8.6) agarose gels in conjunction with the semiautomated Hydrasys instrument using both concentrated and neat urine (60). At least one
position on each gel contained Sebia normal serum control (See Appendix B for full
details of procedure and performance data).
38

3.4.2.1

HR Gel Electrophoresis - Concentrated Urine

Migration of concentrated urine, prepared as described in section 3.3.1, was carried out
at 255 V constant current at 20°C controlled by the Peltier effect. These conditions were
maintained until 75 Vh had accumulated. Drying of the gel was carried out at 60°C for 6
minutes. Gel staining was carried out with Acid Violet stain (60).

3.4.2.2

HR Gel Electrophoresis - Neat Urine

Migration of neat urine was carried out at 255 V constant current at 20°C, controlled by
the Peltier effect. These conditions were maintained until 40 Vh had accumulated.
Drying of the gel was carried out at 60°C for 6 minutes. Gel staining was carried out
with Acid Violet stain (60).

3.4.3

15 plpl Agarose Gel Electrophoresis

Urine protein in concentrated urine samples (described in section 3.3.1) was separated
on alkaline buffered (pH 8.5) gels used in conjunction with the Hydrasys instrument. At
least one position on each gel contained Sebia normal serum control. Migration was
carried out under 20 W constant at 20°C controlled by the Peltier effect until 36 Vh had
accumulated. The temperature of the control plate then rose to 65°C for 10 minutes for
drying of the gel. Amido black was used to stain migrated proteins (72). (See appendix
B for full procedure details and performance data).
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3.5

Densitometric Scanning

Scanning of stained agarose gels was carried out using the Sebia Hyrys Densitometer
which optically reads the density of staining at 570 nm. The instrument then converted
the readings into a protein trace which could be used for peak quantification (g/L and %)
based on area under the curve (AUC) calculations. Peak quantification using the Hyrys
measured the AUC down to the baseline of the trace.

3.6

BJP IdentiHcation

3.6.1

Bence Jones Immunqfixation

Concentrated urine as described in section 3.3.1 was diluted using supplied diluent to a
protein concentration of 5.0 g/L. Migration of samples on the gel is carried out under
20W constant until 42 Vh has accumulated at 20°C. Following antibody application,
incubation was at 20°C for 10 minutes. Blotting of gel to remove excess antibody was
for 3 minutes at 40°C. Gel drying was carried out at 50°C for 6 minutes. All temperature
conditions were controlled by Peltier effect. Acid violet was used to stain the gel (73)
(For full description of procedure and performance data see appendix B).
Note: All urine samples, regardless of the UPE results obtained, were immunofixed with
K and X antisera in order to verify that all positive results were detected by the urine
electrophoresis techniques. Any samples positive by this screen were further
investigated for BJP.

3.6.2

Capillarys Immunotyping

Dialysed urine samples as described in Section 3.3.2 were used for Capillarys
Immunotyping (IT) by immunosubtraction. These dialysed urines were automatically
diluted in the antisera segment diluent which was loaded on board the instrument
simultaneously with the sample. The diluted urine was mixed respectively with ELP
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solution (fixative), anti-IgG, anti-IgA, anti-IgM, anti-K and anti-I. Diluted samples and
reagents were injected into capillaries.
Migration was carried out under constant voltage for four minutes with temperature
controlled by the Peltier effect. Proteins were detected directly by scanning at 200 nm to
produce an electrophoretic profile on the Phoresis software package (64) (See appendix
B for procedure and performance data).

3.7

Interpretation

All samples by all methods were interpreted by the same medical scientist with
background experience in protein electrophoresis interpretation. The protein separations
observed with the various electrophoretic techniques were classified according to the
visible fractions present and interpretation was qualitative. Classification was as follows:
AP

Albumin Present

AA

Albumin and al globulins present

AB

Albumin and p globulins present

ABG Albumin, p and y globulins present.
AAB

Albumin, al and p globulins present

AAAB Albumin, al, a2 and p globulins present
GPR

Generalised proteinuria

AG

Abnormal peak detected

Note: In the case of suspected monoclonal banding which was shown by IFE to be
caused by interference, the status of that particular result was adjusted to reflect the other
protein fractions present and not the interfering band. This reflects the result reporting
policy of the MWRH.
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These interpretations were based on the following:

3.7.1

Capillarys Urine Interpretation

At the end of analysis, the electrophoretic profiles were examined and interpreted
visually for pattern abnormalities on Phoresis. The different protein zone positions
(albumin, al, a2, p and y) are identified on the screen. Abnormal peaks were quantified
using the peak quantification tool which allowed the software to suggest an appropriate
dilution for urine IT. Unlike the Hyrys densitometer, the Phoresis peak quantification
tool is programmed not to quantify peaks down to be baseline of the electrophoretogram.
Interpretation was qualitative. Normal QC electrophoretograms were used to overlay
patients’ samples as a reference pattern to aid interpretation.

3.7.2

HR Gel Electrophoresis Interpretation

Urine HR electrophoresis is used as a screening test for urinary protein. It allows the
detection of monoclonal components (which must be confirmed and identified by IFE)
and the detection of proteins of tubular, glomerular or mixed origin. Interpretation was
carried out based on visual inspection of the protein fractions present on the gel and the
densitometric scan of each sample. Figure 5 illustrates possible protein fractions as
visualised by HR electrophoresis (60).
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Figure 5: High resolution gel separation ofprotein fractions

3.7.3

15 plp2 Gel Electrophoresis Interpretation

Urine 15 pip2 electrophoresis may be used as a screening test for urinary protein. It
allows the detection of monoclonal components (which must be confirmed and
identified by IFE) and the detection of proteins of tubular, glomerular or mixed origin.
Interpretation was carried out based on visual inspection of the protein fractions present
on the gel and the densitometric scan of each sample.

3.7.4

Capillarys Urine IT Interpretation

IT involved the immunological confirmation of the presence or absence of monoclonal
component

and

the

characterisation

of that

monoclonal

component.

A

six

electrophoretogram series of images was produced for each sample, one for each of the
five antibody-sample reactions and one fixative image (reference).
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Using the reference pattern as an overlay, the effect of the individual antibodies on the
urine sample was reviewed. The absence of a previously present abnormal peak in the
presence of specific antisera indicated a positive reaction and the presence of that
particular heavy or light chain in the urine. In the case of a positive suspected free light
chain reaction, further IFE with anti-Kf or anti-)^f was required. This was necessary to
confirm that the

k

or X, band was in fact a free

k

or free X light chain and not an IgD or

IgE monoclonal peak.

3.7.5

Bence Jones Immunofixation Interpretation

In the case of each sample, all 6 IFE lanes were carefully and closely visually inspected
under a bright light for abnormal bands. Any monoclonal bands present should have
been amplified by the antisera used in the IFE procedure.
The presence of BJP was indicated by: the presence of a monoclonal band detected with
one of the anti-free and bound light chain antisera (k or X); the same monoclonal band
detected with the anti-free antisera (Kf or Xf); and no reaction with the trivalent antisera
(6ap).
The presence of a serum paraprotein eliminated in the urine without Bence Jones was
indicated by: the presence of a monoclonal band detected with one of the anti-free and
bound light chain antisera (k or X); no monoclonal band detected with the anti-free
antisera (Kf or Xf); and a monoclonal reaction with the trivalent antisera (6ap).
In cases where BJP and intact monoclonal immunoglobulin were present in urine a
combination of the above patterns would be evident.
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3.8

Statistical Analysis

Statistical analyses were performed using Excel (Microsoft Office 2007) and SPSS
software. The Kolmogorov-Smimov test was used to test the numerical data for
normality. The correlation coefficients were tested by Spearman’s Rho to assess
significance. The medians were tested for significant differences using the nonparametric Wilcoxon signed rank test. Values of P <0.05 were considered to be
statistically significant.
The ranked qualitative data was assessed for association by the Chi-Square test. Cohen’s
kappa was used to measure agreement between methods, with a Cohen’s kappa of 1
signifying perfect agreement.
For statistical manipulation purposes only, to limit the number of ranks, results were
classified into four categories according to the following interpretations:

Categories
Glomerular

Tubular

Mixed

Overflow

Urine

AP

AA

GPR

AG

Electrophoresis

ABE

AAB

Interpretation

ABC

AAAB

Table 1: Classification ofUPE interpretations for statistical analysis
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4.0

Results

4.1

Urine Electrophoresis

For comparison purposes the technique currently in use in the MWRH for UPE, the
Hydragel pip2 Agarose gel method, was used as the standard against which all other
methods were compared. The results of 88 random urine samples with a mean urinary
protein concentration of 1.18 g/L and values ranging between 0.15 g/L and 10.74 g/L
were used in the comparisons. (For complete result tables and full statistics see
appendices C and D).

4.1.1

Capillarys Urine v*s Hydragel

(Existing Method)

At interpretation, samples 001 to 090 processed by the Vivaspin 6ml urine dialysis
,

technique described in section 3.3.2.1, were found to be very difficult to interpret and
showed low resolution. Consultation with the Capillarys Urine product manufacturers
revealed that this previously recommended pre-analytical treatment was no longer
recommended and that all samples, to ensure clarity and ease of interpretation should
undergo pre-analytical dialysis treatment with the Sebia 20 ml Dialysis System. All
samples considered below were reprocessed using the Sebia 20 ml Dialysis system
described in section 3.3.2.2.

The Capillarys urine technique for urinary protein electrophoresis showed complete
agreement with the existing method in 43 of the 88 samples analysed. The results
showed a significant association between the methods with P <0.001, indicating good
agreement. Cohen’s kappa was 0.450, again indicating good agreement.

Although variations were seen in the type of proteins visualised after migrations
between the two methods, the Capillarys Urine method detected all of the monoclonal
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bands detected by the existing method. Of the 88 urines analysed, 21 contained
monoclonal proteins, the Capillarys Urine reported two false positive (015, 065) and five
false negative results (004, 017, 046, 055, 076) when this is compared with the two false
positives (065, 098) and five false negative (004, 017, 046, 055, 076) results of the
Hydragel plp2 method it indicates that the both methods have the same level of
specificity (97.0%) and sensitivity (76.2%).

4.1.2

Hydragel HR Neat

Hydragel plp2

The Hydragel HR neat technique showed complete agreement with the existing method
in 58 of the 88 samples analysed, the highest level of agreement seen of the three
methods compared. The results showed a significant association between the methods
with P <0.001, indicating good agreement. Cohen’s kappa was 0.655, also indicating a
high level of agreement.
Again, variations were seen in some samples with suspected monoclonal bands
visualised after migration and staining. Of the 88 urines analysed, 21 of which contained
monoclonal proteins, the Hydragel HR neat reported two false positive results (065, 098)
and four false negative results (017, 046, 055, 076) when this is compared with the two
false positives (065, 098) and five false negative (004, 017, 046, 055, 076) results of the
Hydragel

pip2

method

it

indicates that the both methods have the same

specificity(97.0%) but that the HR method has higher sensitivity (81.0%) than the pip2
method.

4.1.3

Hydragel HR Cone, v’s Hydragel plp2

The Hydragel HR Cone, technique showed complete agreement with the existing
method in 56 of the 88 samples analysed. The results showed a significant association
between the methods with P <0.001, indicating good agreement. Cohen’s kappa was
0.624, again indicating high levels of agreement.
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Again variations were seen in some samples with suspected monoclonal bands
visualised after migration and staining. Of the 88 urines analysed, 21 of which contained
monoclonal proteins, the Hydragel HR Cone, method reported five false positive results
(015, 058, 065, 098, 120) and three false negative results (017, 046, 055) when this is
compared with the two false positive (065, 098) and five false negative (004, 017, 046,
055, 076) results of the Hydragel pi P2 method it indicates that the HR method has lower
specificity (92.5%) but higher sensitivity (85.7%) than the plp2 method for the detection
of monoclonal components. Figure 6 illustrates the gel and chromatogram images
obtained following analysis of one sample which showed the presence of a monoclonal
component detected only by the high resolution gel methods.

HR
Cone.

HR
Neat

B1B2

Capillarys Urine

K/k antisera
Screen

i« U

Figure 6: Urine protein gel and capillary electrophoresis of sample (004) which contained an
M-component only detected by the high resolution gel methods.
Note: Location of M-component is denoted by arrows.
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4.2

M-Component Quantification

Overall, twenty one bands of varying signal strength were detected by the gold standard
for BJP detection and identification, IFE. Three samples with abnormal bands detected
by IFE, {017, 046, 055), were not shown to be positive for abnormal banding by any of
the four UPE techniques employed here. Eighteen of the bands or peaks were detected
and quantifiable by one or more of the UPE methods used to screen for them, using
either densitometry or the Phoresis software peak quantification tool.

Again, the method currently in place for abnormal band quantification in the MWRH,
Hydragel plp2 combined with densitometry, was used as the standard against which the
other methods were compared. In the case of all of four methods examined, the
Kolmogorov-Smimov test of normality established that the measurements were not
normally distributed. (For full results table see appendix C).
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4.2.1

Peak Quantification: Capillarys Urine v*s Hydragel plp2

The median value of the Hydragel pip2 was 41.75 g/L and that of the Capillarys urine
was 29.3 g/L. The medians were tested for significant differences using the nonparametric Wilcoxon signed rank test and the difference between the medians of the
Capillarys urine and Hydragel pip2 methods, p = 0.008, was significant. Spearman’s rho
correlation for non-parametric data gave a correlation coefficient of 0.839 indicating
high correlation. Graph 1 illustrates the relationship between measured values of the two
methods.

Peak Quantifications: Capillarys Urine v's Hydragel ^1^2

Graph 1: Plot of Capillarys Urine Peak Quantification v’s Hydragel pip2 Peak
Quantification
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4.2.2

Peak quantiHcation: Hydragel HR Neat v’s Hydragel pip2

The median value of the Hydragel plp2 was 41.75 g/L and that of the Hydragel HR neat
was 46.6 g/L. The medians were tested for significant differences using the nonparametric Wilcoxon signed rank test and the difference between the medians of the
Hydragel HR neat and Hydragel plp2 methods, p = 0.07, was not significant.
Spearman’s rho correlation for non-parametric data gave a correlation coefficient of
0.944 indicating high correlation. Graph 2 below illustrates the relationship between the
measured values of the two methods.

Peak Quantifications; Hydragel HR Neat v's Hydragel ^1|32
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Graph 2: Plot of Hydragel HR neat Peak Quantification v’5 Hydragel flf2 Peak
Quantification
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4.2.3

Peak quantification: Hydragel HR Cone, v’s Hydragel plp2

The median value of the Hydragel pip2 was 41.75 g/L and that of the Hydragel HR
Cone, was 41.2g /L. The medians were tested for significant differences using the nonparametric Wilcoxon signed rank test and the difference between the medians of the
Hydragel HR neat and Hydragel plp2 methods, p = 0.349, was not significant.
Spearman’s rho correlation for non-parametric data gave a correlation coefficient of
0.971 indicating high correlation. Graph 3 below illustrates the relationship between the
measured values of the two methods.

Graph 3: Plot of Hydragel HR Cone. Peak Quantification v’s Hydragel flf2 Peak
Quantification
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4.3

IT and Bence Jones Immunofixation

All samples processed by Capillarys Urine, regardless of protein pattern, were also
immunotyped using the Capillarys IT Urine test.
As was the case with UPE by Capillarys Urine, at interpretation, samples 001 to 090,
processed by the Vivaspin 6ml urine dialysis technique described in section 3.3.2.1,
were found to be very difficult to interpret and showed low resolution. Consultation with
the Capillarys Urine product manufacturers revealed that this previously recommended
pre-analytical treatment was no longer recommended and that all samples, to ensure
clarity and ease of interpretation should undergo pre-analytical dialysis treatment with
the Sebia 20 ml Dialysis System. All samples considered below were reprocessed using
the Sebia 20 ml Dialysis system described in section 3.3.2.2.

Twenty one samples were found to contain a monoclonal component by Bence Jones
IFE while only sixteen samples were found to contain a monoclonal component by IT.
This indicated that 5 samples containing a monoclonal component, two free k, two free X,
and one IgG/A/M X, were found to be negative by the IT technique. Thus, the sensitivity
of IT was found to be 76.2% (See appendix C for full result table).
Additionally, of the sixteen bands which were identified, five were misclassified as
follows:
Sample Number

Immunofixation Result

IT Result

001

Free K + IgG/A/M k

Biclonal

k

002

Free k + IgG/A/M k

Biclonal

k

030

Free X + IgG/A/M X

Monoclonal X

031

Free K + IgG/A/M k

Biclonal k

035

IgG/A/M K

Monoclonal

Table 2: Misclassification of Monoclonal peaks by IT
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k

5.0

Discussion

Proteinuria is one of the main symptoms of kidney disease and when changes occur in
the amount or composition of urinary protein it becomes an indicator of pathological
processes (74). Irrespective of the causes of proteinuria, there is increasing evidence
suggesting the harmful secondary effects of this protein flow on the kidney. A strong
statistical relationship between the magnitude of proteinuria and the rate of decline of
renal function has been reported to exist in most renal disorders (2, 3, 17, 30), therefore
the detection, classification and monitoring of this often treatable condition are
important clinical tools.

Many different diagnostic approaches exist for the investigation of urinary protein type
in the proteinuric patient, including various types of gel and capillary electrophoresis.
No published research or specific guidelines exist however, to suggest a method of
choice for the analysis. The clinical method used to assess proteinuria should be
accurate, sensitive, rapid, inexpensive and free from overly cumbersome features.

Bence Jones Proteinuria and M-component identification and classification are
important parts of the diagnosis and monitoring of neoplastic conditions such as MM or
Waldenstrom’s macroglobulinemia. According to guidelines published in 2003 by
Graziani et al, IFE of a concentrated urine sample is the recommended method for
typing BJP (23). Although immunoassays are available for the direct measurement of
free light chains (26, 75, 76), it is widely believed that there is no anti-sera in existence
than can distinguish polyclonal from monoclonal free light chains in either serum or
urine and therefore, urinary monoclonal peak quantification is the only reliable tool
available to clinicians (23, 77, 78). Since BJP peak quantification is used in monitoring
response, relapse, remission and the staging of MM, the ability of electrophoretic
methods to produce accurate and reliable quantification of peaks is critical.
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This study compared (3ip2 agarose gel electrophoresis with urine CZE and high
resolution gel electrophoresis in order to establish a method of choice for urine protein
separation. As part of the research, examination of the ability of a new
immunosubtraction technique to classify monoclonal peaks in urine was carried out.
The study also looked at the peak quantifications obtained by each electrophoretic
method in samples containing a monoclonal component. It was decided to omit the
comparison of each technique’s limits of detection in detecting M-components. This was
decided based on the fact that huge inter-patient variability exists in urinary Mcomponents, particularly BJP, and that commonly BJP may be found migrating co
incident with other globulin bands (60, 67). For these reasons, the establishment of each
technique’s limit of detection would not be a true reflection of its ability to identify
urinary M-components in a large percentage of patients.

The method currently in use in the MWRH, Hydragel pi(32 agarose gel electrophoresis
was used as the method against which the other techniques were compared and as is
laboratory policy, only urine specimens with protein concentrations of greater than or
equal to 0.15 g/L were electrophoresed. Since electrophoresis is quite a time consuming
and labour intensive process this cut-off helps exclude urines containing physiological
levels of protein and urines which exhibit a high level of background interference. In
support of this, previous studies have found that the sensitivity and specificity of UPE by
CZE was inadequate below a protein concentration of <0.1 g/L. Samples below this
urinary protein threshold were found to give electrophoretograms with horizontal line
traces and small peaks which were interpreted incorrectly as monoclonal peaks, while in
other cases background noise artefacts masked the presence of genuine abnormalities
(54).

Urine Protein Electrophoresis
Examination of the results of the UPE techniques showed good agreement between the
three comparison methods and the existing method. The closest relationship was seen
between the Hydragel HR neat and the Hydragel pip2 gel. Hydragel HR Cone, also
showed very similar results but with slightly less agreement. The least association was
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observed between the Capillarys Urine and the Hydragel pip2 gel techniques, however
overall the difference in agreement between the three methods was not high. As has been
highlighted in previous studies, a major advantage of urine CZE is its shorter analysis
time when compared with conventional gel electrophoresis methods (1, 14), the benefit
of this shortening of analysis time however, is negated by a time consuming, labour
intensive sample preparation step required prior to sample analysis.

A major advantage of the Hydragel HR neat method is that there is no requirement for a
concentration or dialysis step prior to electrophoresis, neat urine is applied directly to the
agarose gel. Not only does this reduce cost and eliminate the time spent concentrating
the sample, it also rules out possible interferences caused by the concentration step. It
has been widely reported that the mechanical concentration of urine prior to
electrophoretic analysis can alter protein composition and even lead to the loss of low
molecular weight proteins such as BJPs from samples (21, 25, 29).

Of particular importance to the routine clinical chemistry laboratory is the detection and
quantification of monoclonal components. Of the 88 urine samples analysed, 21
contained monoclonal proteins. As stated previously, the ability of a UPE technique to
detect any monoclonal components present is critical as the consequence of false
negative results can be huge. Capillarys Urine, Hydragel pip2 and Hydragel HR neat
methods all displayed similar levels of specificity, with the HR neat technique showing a
higher level of sensitivity than the other two methods. In contrast, the Hydragel HR
Cone, technique displayed a considerably lower standard of specificity than the other
three methods. The level of sensitivity observed however, was the highest of all the
methods examined. The finding of higher levels of sensitivity with the use of HR gels, as
illustrated in figure 6, is in agreement with a previous study which found HR gel
techniques better capable of detecting subtle monoclonal components than other
methods (55). In contrast, studies of serum protein electrophoresis have shown that CZE
provides better sensitivity in detecting monoclonal components in serum than agarose
gel electrophoresis (79), this clearly does not hold true in the case of urine.
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It is also worth noting that the samples processed by the Hydragel HR Cone, technique
were concentrated to a protein concentration of 20 g/L as opposed to 5g/L as suggested
in the kit insert. This increase in concentration undoubtedly contributed, to some degree,
to the higher sensitivity and lower specificity observed with this technique.

Another important observation was the high level of false positive results recorded by
the HR Cone, technique. Although it may be regarded as less significant from a clinical
point of view, a high rate of false positive screens for BJP, which would result from the
use of a UPE technique which lacks specificity, is both time consuming and expensive in
terms of reagents and work force. In a busy clinical laboratory this must be taken into
consideration when a new technique is being examined.

M-Component Quantification
A BJP screen, using antisera against

k

and X immunoglobulin light chains was carried

out on all samples irrespective of protein pattern to ensure that any samples with
negative UPE results were in fact true negatives. This screen uncovered three samples
which were IFE positive but UPE negative by all methods. Two of the samples {046,
055) showed weak bands on IFE which it appeared, required the higher sensitivity and
antibody amplification provided by the BJP IFE in order to be detected. In the case of
the third sample, (017), the abnormal band co-migrated with the beta globulin band in a
urine with a generalised proteinuria pattern and a high measured urinary protein of 4.34
g/L. As MM is often associated with renal disease, additional bands along with a
monoclonal component may be excreted in the urine. Co-migration of such BJP with
these proteins has been reported previously in the literature and may hinder proper
identification and quantification of the monoclonal peaks (25). Cases such as this
highlight the importance of Bence Jones IFE in patients where there is any clinical
suspicion of BJP as under no circumstances will UPE ever be able to entirely out rule
the possible presence of a monoclonal component.
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Examination of the peak quantifications obtained by the different techniques highlighted
considerable differences between gel and capillary based methods. The Capillarys Urine
method which employed Phoresis software for peak quantification produced a
considerably lower median than any of the other methods. This may have been due, in
part, to the fact that the Phoresis software did not measure peak quantification down to
the baseline of the electrophoretogram while the methods which employed densitometry
quantified the peak from the baseline. This however is a major factor to consider when
peak quantification methods are to be changed in a clinical setting, as the implications of
a change in a patient’s monoclonal peak measurement can be great. Ideally in a situation
where a change of technique is required, it is in the best interest of the patient population
to minimise any possible detrimental effects on their treatment. This is reinforced by the
international guidelines of Graziani et al. which emphasise that for maximum patient
benefit of BJP quantification, analytical variability should be minimised at all times
(23).

The difference between the medians of the Capillarys Urine and the Hydragel plp2 was
found to be significant although there was high correlation between the two sets of
results. The plot in section 4.2.1 illustrates the spread observed between the two
methods. Both the plot and the calculated correlation coefficient of the Hydragel pip2
method and both of the Hydragel HR techniques indicate a strong association. All three
gel methods had very similar medians with, HR Cone, and Hydragel plp2 showing the
closest relationship. The close correlation seen between these techniques signifies
minimal effect on patient care should a UPE method change need to be implemented.

Bence Jones Immunofixation/typing
Of the 88 samples processed by both Capillarys IT and IFE, 21 were found to contain
monoclonal components by the gold standard Bence Jones IFE. Of these 21 samples,
when analysed by IT, only sixteen were found to contain monoclonal fractions. Four
samples containing free light chains and one containing intact immunoglobulin as
detected by IFE were reported as negative by the IT technique. This oversight has
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serious implications, as the early detection of plasma cell dyscrasias can greatly
influence patient prognosis and survival (80),

Of the sixteen urine samples found to be positive for M-component by IT, the technique
misclassified five. This is illustrated in table 2 Section 4.3. In one instance it mistyped a
sample with an intact immunoglobulin (IgG/A/M) as a monoclonal kappa. As the IT
assay does not have the capacity to screen for free light chains, all but one of these
sixteen urines, which it correctly typed as IgG X, would have required further
mechanical concentration followed by gel IFE. This would have eventually revealed the
true nature of the M-component in each sample.

There was an apparent inability on the part of Capillarys IT to detect the presence of
intact immunoglobulin excreted in association with a light chain. One possible
explanation is that this may have been due to co-migration of the intact immunoglobulin
with the free light chain in conjunction with an inadequate response from the heavy
chain antisera, it is highly unlikely however that this was the case in all of the
misclassified samples, if any. Based on these findings, it appears that the use of IT for
BJP screening is less reliable, slower and ultimately more labour intensive that the gold
standard of BJP IFE. It would seem improbable that at any time in the future IFE which
is based on immuno-amplification of signal will be replaced by IT which is based on
immunosubtraction of signal.

Practical Considerations
Practical considerations must also be taken into account in the examination of new
methods. The complexity of the method steps, the amount of time taken for sample
processing, the degree of operator intervention required and the level of technical skill
required are all important issues in today’s busy clinical laboratories. Of the four
methods examined, the Capillarys Urine method undoubtedly was the most practically
demanding technique, with a sample preparation step requiring hands on operator
intervention of approximately two hours duration. This was followed by a reasonably
rapid analysis time for both electrophoresis and IT, however, a positive IT result
59

required further confirmation, and therefore an additional mechanical concentration step
and IFE were also necessary. Overall, the complete start to finish processing of urine by
the Capillarys Urine method was found to be extremely time consuming and labour
intensive. It has been suggested in the literature, that as an alternative to sample dialysis,
gel filtration of urine may be a faster and more efficient means of sample preparation
prior to capillary electrophoresis producing a good level of protein recovery (81).
Although at present this type of pre-treatment is not suggested by the manufacturers of
Capillarys Urine, it may serve as an alternative to the current recommendation in the
future.

In contrast, the gel methods which used concentrated urine, Hydragel |31p2 and
Hydragel HR Cone, were far less labour intensive with the major advantage that the
urine concentration step, while slow, was a ‘walk away’ procedure that did not require
hands on operator intervention.

The least labour intensive and least time consuming technique of the four examined was
the Hydragel HR neat method. As no pre-analytical concentration step was required, the
samples were loaded directly onto the gel and a final gel product suitable for
interpretation was ready in approximately one hour. Further investigation of a suspected
BJP would require the additional concentration step to achieve a urinary protein
concentration of 5 g/L, however this would only be necessary in the limited number of
samples containing suspicious bands and as stated before requires minimal operator
intervention.

To summarise, this study has shown Urine CZE to be satisfactory in its ability to
separate urinary proteins, but is slow, labour intensive and unable to reliably
immunotype and quantify M-components. The existing method, Hydragel pi(32 again
was satisfactory in terms of its ability to separate urinary proteins, quantify Mcomponents and identify possible abnormal peaks, but did not match the levels of
sensitivity observed in the high resolution gel electrophoretic techniques. Hydragel HR
Cone, showed the highest sensitivity and the lowest level of specificity of all four
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methods, displaying a high level of false positives results. As urines processed by this
method were over-concentrated by a factor of four, it is not clear whether this method’s
sensitivity would have been this high should the recommended urine concentration have
been used. The final method examined, Hydragel HR neat, showed a higher degree of
sensitivity than the existing method, a similar level of specificity and comparable peak
quantification. This method had the distinct advantage that it did not require a sample
concentration step prior to electrophoresis which, although not observed in the samples
analysed in this study, is well recognised as causing alterations in the composition of the
urine proteins including the loss of BJP (26).

In conclusion, based on the findings of this study, the use of a neat urine sample on a
high resolution gel, followed by Bence Jones IFE of any suspected M-components
should be the procedure of choice when investigating a patient with proteinuria.
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Appendix A

Patient Consent and Information Sheet
Mid-Western Regional Hospital
Biochemistry Department/Out Patients Clinic

1. Title of Study: Capillary Zone Electrophoresis Procedure for Urine Protein Analysis:
Comparison with Established Techniques in Patients with Proteinuria

2. Introduction: Proteinuria means the presence of an excess of protein in the urine.
Some protein in the urine is normal, however too much means protein is leaking through
the kidney. Therefore, proteinuria may be a sign of renal damage. The type and amount
of protein present can indicate the nature and extent of renal damage and so the analysis
of urinary protein is a very useful tool in the diagnosis and monitoring of renal disease.
This study aims to compare four different urinary protein analysis techniques in the
laboratory. The results obtained from the study will allow the pathology department
establish the best method and so will ensure that both patients and doctors are provided
with the highest standard of testing available.

3. Procedures: You will be asked to provide a 20ml urine sample. This sample will then
be tested for protein components by four different techniques.

4. Benefits: This study may be of direct benefit to you and subsequent patients by
allowing the pathology department establish the most effective method of analyzing
protein in the urine. It will ensure that the highest possible standard of results will be
available, thus helping more accurately determine the presence and progression of renal
damage.

5. Risks: None

6. Exclusion from participation: Exclusion criteria include patients less than 16 years
of age and pregnancy

7. Alternative treatment: None
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8. Confidentiality: Your identity will remain confidential. Your name will not be
published and will not be released to any person outside the hospital.

9. Compensation: Your doctors are covered by standard medical malpractice insurance.
Nothing in this document restricts or curtails your rights.

10. Voluntary Participation: You have volunteered to participate in this study. You
may opt out at any time. If you decide not to participate or to opt out, you will not be
penalised and will not have to give up any benefits which you had before entering the
study.

11. Stopping the Study: You understand that your doctor may stop your participation in
the study at any time without your consent.

12. Permission: This research has Mid-Western Regional Hospital Complex Scientific
Research Ethics Committee Protocol approval.

13. Further Information: You may get more information about the study, your
participation in it, you rights or have any other questions answered from Dr. Liam
Casserly who may be contacted at 061-485133. If your doctor learns of important new
information that might affect your desire to remain in the study, he or she will tell you.
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Mid Western Regional Hospital
Biochemistry Department/Out Patient Clinic

Title of Research Study:
Capillary Zone Electrophoresis Procedure for Urine Protein Analysis: Comparison
with Established Techniques in Patients with Proteinuria

PARTICIPANTS CHART NUMBER/P.I.D:
PARTICIPANTS NAME:
PARTICIPANTS SIGNATURE:
DATE:

Date on which the participant was first furnished with this form:

NAME OF PRINCIPAL
INVESTIGATOR:
SIGNATURE:

PHYSICIAN/ SPECIALIST NURSE
NAME:
SIGNATURE:

Statement of investigator’s responsibility: I have explained the nature, purpose,
procedures, benefits, risks of, or alternatives to, this research study. I have offered to
answer any questions and fully answered such questions. I believe that the participant
understands my explanation and has freely given consent.

Keep the original of this form in the participant’s medical record, give one copy to the
participant, and keep one copy in the investigator’s records.
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Appendix B

Test Procedures and Performance Data

Beckman Microprotein Assay Procedure
1

II necessary, load the reagent onto the system as directed in the Quick Reference Guide at the beginning
of this manual or refer to the SYNCHRON LX20 Operations Manual

2. After reagent load is completed, calibration may be required. Refer to the Quick Reference Guide or the
SYNCHRON LX20 Operations Manual for details of the calibration procedure.
3. Program samples and controls for analysis as directed in the Quick Reference Guide or refer to the
SYNCHRON LX20 Operations Manual.
4 After loading samples and controls onto the system, follow the protocols for system operation as directed in
the Quick Reference Guide or refer to the SYNCHRON LX20 Operations Manual.

Beckman Micioprotein Assay Performance Data
EQUIVALENCY
Equivalency was assessed by correlation analysis of patient samples to accepted clinical methods.
CSF (in the range of 22 to 298 mg/dL):
Y (SYNCHRON LX Systems)
N
MEAN (SYNCHRON LX Systems)
MEAN (SYNCHRON CX7 DELTA)
CORRELATION OOEFFfCIENT (r)

=
=
=
=
=

0 992X • 3 40
49
128,4
132.9
0 9957

=
=
=
=
=

0.944X - 1 72
73
64.2
69,8
0 9949

3 range of 12 to 148 mg/dL):
Y (SYNCHRON LX Systems)
N
MEAN (SYNCHRON LX Systems)
MEAN (SYNCHRON CX7 DELTA)
CORRELATION COEFFICIENT (r)

Refer to References (12) for guidelines on performing equivalency testing.

PRECISION
A properly operating SYNCHRON LX System should exhibit precision values less than or equal to the
following:
Table 7.0
1
!

Precision Values

TYPE OF
PRECISION

Within-Run
; Total

---------------------------------- 1 —
SAMPLE TYPE

1 SD

CHANGEOVER
VALUE*

%CV

mg/dL

g/L

mg/dL

g/L

CSF/Urine

2.0

0 02

50 0

05

4.0

CSF/Urine

3.0

0 03

50.0

0.5
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When ihe mean of the test precision data is less than or equal to the changeover value, compare the test SO to the SD guideline given
above to determine the acceptability of the precision testing When the mean of the test precision data is greater than the changeover
value, compare the test %CV to the %CV guideline given above to determine acceptability Changeover value = (SD guideline/CV
guideline) x 1CK3
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SPECIFICITY
To determine specificity equivalent concentrations of albumin and globulin were assayed using this method.
The results are listed below;
Table 4.0 Specificity*
ALBUMIN (mg/dL)

GLOBULIN (mg/dL)

38.0

36.5

81.3
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Sartorius Vivaspin 6 Sample Pre-Treatment Procedure
Samples Dfecaralion Milh'
1. Quantify the total protein concentration In the urine sample to be analyzed
2 Centrifuge 5 mL neat urine at 5 000 rpm tor 10 minutes
3 Collect the supernatant
4. Prepare each sample in a new Vivaspin* 6 ml tube according to Its total protein concentration.
- When ttie total protein concentration is below tOQ mg/dL mu 0.5 mL urine with 5.5 mL distilled or deionized water in the tube.
• When the total protein concentration is between 100 and 300 mgi'dL: mm 0.12S mL urine with 6 mL distilled or deonized water In the tube
• When the total protein concentration is over 300 mg/dL dilute first the urine to a protein concentration ot 300 mg/dL wtth distilled or
deionized water , then mix 0 125 mL diluted urine with 6 mL distilled or deionized water In the tube

5.
6

Homogenize the diluted unne
Equilibrate the tubes with distilled or deionized water and ceninfuge at 3 500 g ' tor 30 minutes
WARNING- Att»r concmniratlon by cantrifugstlon, the voluma oblainad mu$l ba up to 0.1 mL.

7
8
9

Discard the solution conlamed in the lower part of the Vivaspin* tube
Add 6 mL working dialysis butter per Vivaspin* tube
Equilibrate the tubes with working dialysis butter and contrilugo ai 3 500 g ' lor 30 minutes
to Atlor centrilugalion. it the final volume is lower than 0 1 mL. add working dialysis buHor to a linal volume ot 0 1 mL (alter Ihe lower level ol the
meniscus has equilibrated)
11 Homogenize the sample In the tube
12 Take too pL dialyzed unne and apply it directly In the well ol a new grMTt.dlluUOn legmeni.
13 Discard the Vivaspin’! lube
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Sebia Capillarvs 20 ml Dialysis System Procedure
Quantity the total protein concentration in the urine sample to be analyzed
Ceniriluge 5 ml neat ume al 5 000 rpm lor 10 minutes
Collect the supernatant
Prepare each sample in a new CAPILLARVS dialysis system according to its total protein concentration
When the total orotain cpncenttation is belQw IQQ mg/dL max 2 mL urine with 18 mL (Aslilled or deionized watei in the lube
mix 0.5 mL unne with 19 5 mL distilled or deionued water m the lube,
dilute first the urine to a protem concentration ol 300 mg/dL with distilled or deionized
water; then mix 0 5 mL cWuled urine with 19 5 mL distilled or deionized water m the tube
Homogenize the dtuled unne
Equilibrate the tubes with distillsd or deionized water and centntuge at s 000 g ' for 40 mmules
WARNING: After concentration by centrifugation, the eo/ume obtairred muat be up to 0.5 mL.
For dialysis add 20 mL worXmg dialysis buHor per CAPILLARVS dialysis system
Equilibrate the tubes with working dialysis bufter and centntuge at 4 000 g ‘ for 40 minutes
After centrifugation a part of the sample may be left on the upper flat zone of the dialysis system (see the enclosed figure). With a micropipette.
collect this sample and transfer it m the lower well ol the dialysis system. If the final volume is less than 0.5 mL. add working dialysis buffer to a
final volume of 0 5 mL (after the lower level of the meniscus has equihbrated)

10 Homogenize the sample in the tube
It CollecI tlie dialyzed unne remaining m the tube and apply it in a 15 mL microlube
12 Discard the CAPILLARVS dialysis system
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Sebia Hvdragel 31B2 Gel Electrophoresis Procedure
PROCEDURE
The HYDRASYS system is a semi-automated multi-parameter instrument The automated steps include processing ol HYDRAGEL agarose gels in
the following sequence, sample application, electrophoretic migration, drying staining, destaming and final drying. The manual steps include handling
samples and gels, and setting up the instrument for operation
READ CAREFULLY HYDRASYS INSTRUCTION MANUAL

I.

MIGRATION SET UP
1
2.

Switch on HYDRASYS instrument.
Place one applicator lor HYDRAGEL 7 R1 B2 (7 samples) and HYDRAGEL R1-B2 15/30 |15 samples), or two applicators lor HYDRAGEL
B1-B2 15/'30 (30 samples), on a flat surface with the well numbers in the nght-side-up position (Fig. 1).
- Apply 10 pL of neal serum or concentrated urine sample in each welll. Load each applicator within 2 minutes
- Place the applicator(s) into the wet storage chamber with the teeth up. [Handle it (them) by the plastic tooth protection frame). Let the
samples diffuse into the teeth for 5 minutes after the last sample application For later use (up to 8 hours), keep the entire chamber under
refrigeration

3.

Open the lid of the Migration Module and raise the electrode and applicator carriers.
WARNING: Never close the lid while the carriers are raised !
Select "7 B1-B2" migration program lor HYDRAGEL 7 B1-B2 or »15,^30 B1-B2* migration program from the instrument menu (left side ol the
keyboard).
Remove buffered strips from the package : handle them by the plastic ends. Engage the punched ends of the strip's plastic backing to the pins
on the electrode carrier , the strip's plastic backing must face the carrier (Fig. 2).
Unpack the HYDRAGEL plate
Roll quickly and uniformly one thm filter paper onto the gel surface to absorb the excess of liquid Remove the paper immediately

See wet chamber package insert for further details.

4
5
6.

WARNING: Do not leave the filter paper tor a loo long contact with the gel to avoid Us dehydration.

7.
8

Pool 120 pL ol distilled or deionized water for HYDRAGEL 7 B1-fl2, or 200 pL for HYDRAGEL B1-B2 1S-'30, on the lower third of the frame
printed on theTemperature Control Plate of the migration module
Place the gel plate (the gel side up) with its edge against the stop at the bottom of the printed frame (Fig 3)
Bend the gel and ease it down onto the water pool (Fig. 3). Ensure that no air bubbles are trapped, water is spread underneath the entire
gel plate and the gel is lined up with the printed frame.
Lower both carriers down. In this position the buffered strips do not touch the gel DO NOT FORCE THE CARRIERS ALL THE WAY DOWN
Remove the applicator(s) from the wet chamber. Handle it (them) by the protection frame.
Snap off the applicator teeth's protection frame
- For 7 and 15 samples analysis, place the aplicator into position No 6 on the carrier
- For 30 samples analysis, place the two applicators each into position No 3 and 9
IMPORTANT: The numbers printed on the applicator(s) must face the operator (Fig. 4),

9. Close the lid ol the migration module
10. Start the procedure immediately by pressing the green arrow -START- key on the left side of the keyboard
IMPORTANT: Make sure that the ventilation air inlet on the right side of the instrument is not blocked.

MIGRATION - DESCRIPTION OF THE AUTOMATED STEPS
• The two carriers are lowered so that buffered strips and applicator(s) contact the gel surface
■ Sample applicator earner rises up
• Migration is carried out under 10 W constant lor HYDRAGEL 7 B1-B2 or 20 W constant for HYDRAGEL B1-fl2 1530, at 20 C controlled by Peltier
effect, until 36 Vh have accumulated, for about 7 minutes
• The electrode carrier rises to disconnect the electrodes
• The temperature of the control plate rises to 65 “C for 10 minutes to dry the gel
• The control plate is cooled down when it reaches 50 X, an audible beep signals that the migration module lid unlocks The plate temperature
remains at 50 "C until the lid is opened Then, the temperature keeps deaeasing until it reaches 20 X (m less than 5 minutes) after which a now
migration run may start
NOTE. The migration module hd remains closed dunng all migration steps

II. GEL PROCESSING SET-UP
1
2
3
4
5
6.
7

Open the lid.
Remove the applicator(s) and discard
Raise both carriers, remove the buffered strips by their plastic ends and discard
Remove the dried gel film for further processing.
After each use, wipe the electrodes and the temperature control piiate with a soft wet tissue.
Open the Gel Holder Lay it flat and position the dried gel (with gel side facing up) into the grooves of the two rods and close the holder Make
sure that the Mm is correctly positioned inside the holder (Fig. 5)
Place the gel holder into the Gel Processing / Staining Module
IMPORTANT: Before starting the gel processing

staining program, check the following

- the staining container is filled with 300 mL ol staining solution :
- the destaming container contains at least 1 liter ol destaming solution :
the waste container is empty
For reagent line connection, refer to the information displayed on the screen ol the instrument (select key; REAGENT LINES)
IMPORTANT: Do not forget to block up the unused lines.
8

Select <-PROT.'Bl-B2'Hb" staining program from the instrument menu and start the run by pressing the -START- key (green arrow on the
right side of the keyboard)
During staining, destaming and drying steps, the compartment remains locked
Alter cooling step, an audible beep signals that the compartment unlocks (the ventilation is maintained until the gel holder is removed).
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Sebia Hvdragel B1 [32 Gel Electrophoresis Performance Data
Concentrated urines analysis
Results obtained with HYDRAGEL I31-R2 15/30 gels indicate a very good reproducibility within and between runs lor concentrated urines samples after
quantitative and qualitative analysis. Twenty eight (28) dltterent samples (pathological and normal urines) were run on HYDRAGEL 01-02 15/30 gels
and another commercially available agarose gel system. There were no visually detectable differences among the two systems. The sensitivity of
detection was determined from the highest serial dilutions of a monoclonal unnary protein giving a discernible band at 0.024 g/dL.

Sebia Capillarys Urine Procedure
I.

PREPARATION OF ELECTROPHORETIC ANALYSIS
1
2.
3.

4.

Switch on CAPILLARYS instrument and computer
Launch the software, the instrument automatically starts
The CAPILLARYS instrument must be used with "URINE" analysis program and the CAPILLARYS PROTEIN(E) 6 buffer To soled "URINE"
analysis program and place the CAPILLARYS PROTElN(E| 6 buffer vial m the instrument please read carefully the CAPILlARYS instruction
manual
Normalize the capillaries with the Normal Control Serum (see the paragraph "Reagents required but not supplied'').
IMPORTANT: It is necessary to normalizo the capillaries before urine samples analysis
them afterwards with CAPILLARYS IMMUNOTYPINQ URINE procedure

5

the CAPILLARYS instrument in order to analyze

■ Apply 25 pL reconstituted Normal Control Serum in a homolysing tube and 2 mL of wofiring (Salysis buffer . then, homogenize.
- Place this tube m position No 1 on the sample racK No. 0 ol the CAPILLARYS instrument intended lor control sample, and a new green
dilution segment A message will be displayed when the segment Is missing
• Start the analysts Slide the sample rack No. 0 into the CAPILLARYS system, select -Normal ControT n the window which appears on the
screen and validate
The results are then automatically consideied by the software for the data analysis.
Analyse the urine samples prepared with the CAPILLARYS URINE kit
- The sample rack contains eight positions lor lubes Place eight empty hemolysing tubes (used as holders) on each sample rack, and then,
the microtubes containing the dialyzed urines samples Cut the cap ol each microlube belore using it
• Keep the cap ot each mcroiubo for further storage ol samples, if necessary.

IMPORTANT; It Is recommended to identity each heinotysmg tube holding the microlube which contains samples to analyze, with the specific
sample identification bar code label corresponding to the sample. This identification allows to determine the necessary dilution program to
apply when performing the CAPILLARYS IMMUNOTYPINQ URINE technique.
The bar code ot each lube must be visible in the openings of the sample rack
NOTE If the number ot samples to ana/yze is less than 8. complete the sample rack with tubes containing disiiMed or deronizeO water

6.
7

Place a now green dilution segment on each sample rack. A message will be displayed if the segment is missing
■ Slide the complete sample camef(s) into the CAPILLARYS system through the opening in the middle of the instrument Up to 13 sample
racks can be introduced successively and continuously into the system
Remove analyzed sample racks from the plate on the left side ol the instrument.
Take oH carefully used dilut«n segments from the sample rack and discard them
WARNING: Dilution segments with biological samples hsve to be handled with care.

8

Take off microtubes containing analyzed urine samples from the sample rack and store them relngeraled (between 2 and 8 "C) lor luriher
analysis with CAPILLARYS IMMUNOTYPINQ URINE technique, if necessary

DILUTION - MIGRATION ■ DESCRIPTION OF THE AUTOMATED STEPS
1
2
3.
4
5
6.

Bar codes are read on sample racks and on lubes with unne samples to analyze
Samples are applied in dilution segment and the dilution needle is rinsed after each sample
Capiltaries are washed
Samples are injected into capillaries
Migration is carried Out under constani voltage, controlled by Peltier ellect lor about 4 minutes
Proteins are delected directly by scanning at 200 nm and an electrophoretic profile appears on the screen ol the system.

NOTE: These steps are described tor the first introduced sample rack The electrophoretic patterns appeal alter tO rrunutes. For the loilowing sample
rack, the steps ) and 2 (bar codes reading and sample application) are made during the step 5 ol the previous sample rack

II. RESULT ANALYSIS
At the end ol the analysis, the electrophoretic profiles can be analyzed and interpreted visually for pattern abnormalities The different protein zone
positions (Albumin. Alpha-t, Alpha-2, Beta and Gamma) are identified on the screen and on the result report
NOTE: For each of the 3 sample preparation procedures, the extent ol the partem visualized on the y-axis on the screen lakes info account tne total
protein concentration m each analyzed sample
Abnormal fractions must be integrated using the "quantify peaks" loot of ihe soflware, then, the "Ralio unne". defined by ihe proportion of the abnormal
fraction area related to Ihe Normal Control Serum proteins total area, is automatically calcutated . it will be displayed in the modify curves window
This ratio will be used in the CAPILLARYS IMMUNOTYPINQ URINE technique to determine the sample dilution program to apply (" HYPOGAMMA “
• STANDARD " or" HYPERGAMMA").
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Sebia Capillarys Urine Performance Data
PERFORMANCE DATA
Standard maienal!i. sample preparation and procedures were used. All electropticregrams were evaluated visually

Reproducibility within run
Reproducibility within run was demonstrated on two different pathologicai urme samples (one urine sample containing live protein fractions and one
sample with a Bence Jones proten) and on one normal sample (physiological urine). Each sample was prepared with dialysis buffer from two different
lots, then applied m all wells of dilution segments and analysed using CAPILLARYS URINE procedure with the same analysis buffer
All repeats gave concordant results within njn and within the two dialysis buffer lots Patterns corresponded to the type of each tested sample
With CAPILLARYS URINE procedure, the unnary proteins were correctly identified in the two pathological samples, there were no false positives and
no differences were observed among the repeats. No prolom was detected with the normal sample

Reproducibility between runs and lot-to-lot
Reproducibility between runs was demonsbated on six different pathotogicai urine samples containing one to seven protein fractions and on two
normal samples (physiological urines) prepared each with dialysis buffer from three different lots.
These samples were analyzed 10 times using CAPILLARYS URINE procedure for each dialysis butter lot and with the same analysis buffer.
All repeats gave concordant results between runs and lot to-lot
With CAPILLARYS URINE procedure, the urinary proteins were correctiy identified in the six pathological samples, there were no false positrves and
no differences were observed among the repeats For each unne sample tested, typical pattern and specific urinary proteins were detected as
expected for each sample type. No abnormal protein was detected with the normal samples.

Concordance Study
Concordance study was performed on 100 unne samples between CAPILLARYS URINE procedure and a commemally available agarose gel
electrophoresis system lor urine analysis (without any unne concentration): 19 normal unne samples and 81 different pathological urines have been
run on both techniques the total protein concentrations were comprised between 0 07 and 19 83 gA.
This study demonstrated a tOO % agreement between the two techniques
> For the 19 normal unne samples: complete agreemeni (concordance).
■ Fcr the 81 pathological urine samples complete agreement (concordance).
For all the analyzed pathological urine samples the results obtained with the individual procedures were in agreement and the urinary protein tractions
were detected on all pathological samples with each system

Sensitivity
Serial ciiutions were prepared with one pathological unne sample containing a Bence Jones protein (at concentration about 0 34 g/L) diluiad in normal
urme and analyzed using the CAPILLARYS URINE procedure.
The minimal detection timii o( the monocional component was about 2.0 mg/dL
NOTE: According to the position of the monoclonal component and polyclonal background m the gamma and beta zones, the defection kmit may vary

Sebia High Resolution Gel Electrophoresis Procedure
PROCEDURE
The HYDRASYS system is a semi-automated multi-parameter instrument. The automated steps irKlude processing ol HYDRAGEL agarose gels in
the following sequence: sample application, electrophoretic migration, drying, staining, destaining and tinal drying The manual steps include handling
samples and gels, and setting up the instrument tor operation
READ CAREFULLY HYDRASYS INSTRUCTION MANUAL

I.

MIGRATION SET UP
1.
2

Switch on HYDRASYS instrument
Place one applicator on a Hat surface with the well numbers in the right-side-up position (Fig 1).
■ Apply 10 pi of sample in each well Load each applicator within 2 minutes.
Place the applicator into the wet storage chamber with the teeth up [handle it by the plastic tooth protection tramej. Let the samples diffuse
into the teeth lor 5 minutes after the last sample application For later use (up to 6 hours). Keep the entire chamber under refrigeration See
wet chamber package insert tor further details
3. Open the lid of the Migration Modulo and raise the electrode and applicaloi earners.
WARNING: Never dote the lid while the carriers are raised I
4 Select migration program from the instrument menu (left side ot the keyboard).
■ '7/15 HRI* mioralion orooram : For undiluted or diluted serum on HYDRAGEL 7 HR and HYDRAGEL 15 HR,
~7, tS HR2~ mioraiion orcMram For diluted serum, concentrated CSF and concentrated urines on HYDRAGEL 7 HR and HYDRAGEL
15 HR.
- •7/15 HR3' minrahon program For unconcenlraled urines on HYDRAGEL 7 HR and HYDRAGEL 15 HR
5. Remove buttered strips from the package : harxfie them by (he plastic ends. Engage the punched ends of the strip's plastic backing to the pins
on the electrode carrier ; the strip's plastic backing must lace the carrier (Fig. 2)
6 Unpack the HYDRAGEL plate
' Roll quickly and uniformly one thm tiller paper onto the gel surface to absorb the excess ot liquid. Remove the paper immediately
WARNING: Do not leave the filter paper lor a too long contact with the gal to avoid Its dehydration.
- Pool 120 pi of distilled or deonized water tor HYDRAGEL 7 HR or 200 pi (or HYDRAGEL 15 HR on the lower third of the frame printed on
the Temperature Control Plate of the migration module.
■ Place the gel plale (the gel side up) with its edge against the stop at the bonom ot the printed frame (Fig. 3).
• Bend the gel and ease it down onto the water pool (Fig 3) Ensure that no air bubbles are trapped, water is spread underneath the entire
gel plate and the gel is lined up with the printed frame.
7 Lower both earners down. In this position the buffered strips do not touch the gel. DO NOT FORCE THE CARRIERS ALL THE WAY DOWN
8 Remove the applicator from the wet chamber Handle it by the protection frame.
Snap oft the applicator teeth's protection frame
' Place the applicator into position No 5 on the carrier
IMPORTANT: The numbers printed on the applicator must face the operator (Fig. 4)
9 Close the lid ot the migration module
10 Start the procedure immediately by pressing the green arrow -STARTu key on the left Side of the keyboard
IMPORTANT: Make Sure that the ventilation air inlet on the right side of the instrument is not blocked.
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MIGRATION - DESCRIPTION OF THE AUTOMATED STEPS
• The two carriers are lowered so that buffered strips and applicator contact the gel surface
• Sample applicator carrier rises up
• '7/15 HRf and *7M5 HR2' migration programs : Migration is carried out under 255 V constant current, for HYDRAGEL 7 HR and HYDRAGEL
15 HR, at 20 °C, controlled by Peltier effect, until 75 Vh have accumulated, for about 18 minutes.
• *715 HR3' migration program Migration is earned out under 255 V constant current, for HYDRAGEL 7 HR and HYDRAGEL 15 HR, at 20 ^C.
controlled by Peltier effect, until 40 Vh have accumulated, for about 10 minutes.
• The electrode carrier rises to disconnect the electrodes
• The temperature of the control plate rises to 60 'C for 9 minutes to dry the gel.
• The control plate is cooled down ; when it reaches 50 'C, an audible beep signals that the migration module lid unlocks The plate temperature
remains al 50 "C until the lid is opened. Then, the temperature keeps decreasing until it reaches 20 ”C (in less than 5 minutes) after which a new
migration run may start
NOTE: The migration module lid remains closed during all migration steps
II. GEL PROCESSING SET-UP
1 Open the lid.
2 Remove the applicator and discard.
3 Raise both carriers, remove the buffered strips by their plastic ends and discard.
4 Remove the dried gel film for further processing
5 After each use. wipe the electrodes and the temperature control plate with a soft wet tissue.
6 Open the Gel Holder. Lay it flat and position the dried gel (with gel side facing up) into the grooves of the two rods and close the holder. Make
sure that the film is correctly positioned mside the holder (Fig. 5).
7 Place the gel holder into the Get Processing . Staining Module

8

IMPORTANT: Before starling the gel processing / staining program, check the following
■ the staining container is filled with 300 mL of staining solution ;
' the destaming container contains at least 1 liter of dastammg solution ,
■ the waste container is empty.
For reagent line connection: refer to the information displayed on the screen of the instrument (select key REAGENT LINES)
IMPORTANT: Do not forget to block up the unused lines
Select -HR ACID VIOLET- or -HR AMIDO- staining program from the instrument menu and start the run by pressing the -START- key (green
arrow on the right side of the keyboard)
During staining, destaining and drying steps, the compartment remains locked
After cooling step, an audible beep signals that the compartment unlocks (the ventilation is maintained until the gel holder is removed)

III. GEL PROCESSING COMPLETION
1
Remove the gel holder from the compartment, open it and remove the dried gel
NOTE : Alter get staining destaining and before densitometry r scanning, a gel may be put through an additional wash step, if needed, to
further clanfy the gel background and to remove any residual stem that may appear as blue spots. Wash the gel using the 'WASH
ISOENZ'GSi' program
2. If needed clean the back side (the plastic support side) of the dry film with a damp soft paper.
3. Interpret the separations visually for pattern abnormalities. The visual observations may be completed by densitometry at 570 nm or with a
yellow filter to Obtain semi-quantitative, relative values for the individual or combined protein fractions

Sebia Hvdragel High Resolution Performance Data
Qualitative analysis
Results obtained on HYDRAGEL 7/15 HR gels indicate a very good reproducibility within and between gels for all the tested aspects and there were
no visually detectable differences among the repeals.
Pathological and normal serum samples, CSF / serum pairs and urine samples from 116 patients were run on HYDRAGEL 7/15 HR gels and on
comparable commercially available high resolution gels. The samples were prepared as recommended by the respective procedures.
Similarities / dissimilarities of the electrophoretic patterns and the presence of monoclonal or oligoclonal bands were the basis lor comparison. The
visual, qualitative comparison between these two tests has been based on the number of bands and their location.
The results of the two procedures were in agreement in all 116 samples and were consistent with the clinical diagnosis.
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Seml-quantative analysis
For the semi-quantilative applications, results obtained with HYDRAGEL 7/15 HR gels indicate a very good reproducibility within and between gels for
all the tested aspects and there were no visually detectable differences among the repeats, the mean CV was 4.0 %.
The HYDRAGEL 7/15 HR procedures with acid violet and amidoWack staining alternatives were compared to another commercially available high
resolution gels procedure (traditional high resolution separations of serum proteins and acid violet staining).
For the sake of comparison, all electrophoregrams were scanned (yellow filler) as 5-zone separations.
Clinical serum samples (n - 56) were run with each procedure and the relative concentrations for each fraction were compared using linear regression
analysis, 0.973 being the mean coefficient correlation for all protein fractions with both staining solutions.
HYDRAGEL 15 HR (acid violet)
FRACTION

Coetiicient

Slope

ymtercept

correlahoo

HYDRAGEL IS HR (amidoblack)
Range(%)

Coeflloent

(HYDRAGEL IS HB)

correlation

Slope

y-tntercept

Range(%)
IHYORAGELISHR)

Albumin

0.981

098

1.89

36.7 -66.1

0.985

0.96

2.35

Alpha-1

0.976

0.99

-0.11

1.5-7.5

0.982

0.97

•0.03

1.3-7.1

Alpha-2

0.982

0.98

-0.14

6.8-24.5

0.978

0.96

0.31

5.7 - 24.2

Beta

0.956

0.91

0.90

5.8 - 19 8

0.918

0.95

0.41

5.4 - 20.0

Gamma

0.991

0.99

■0.16

8.3-40 0

0.990

0.94

1.05

7.2-37.5

36.1 -67.4

Sensitivity
A pathological serum containing a monoclonal component (identified and quantitated by other means) was serially diluted with a normal serum and
the individual dilutions electrophoresed using »HR1» and «HR2» programs. Similarly, a urine sample containing albumin and Bence Jones protein
(identified and quantitated by other means) was serially diluted and electrophoresed using - HRS* program. The sensitivity was determined from the
highest serial dilution giving a discernible band upon staining with acid violet. On the "HR1- and «HR2» programs the sensitivity of detection was
to - 30 mg/dL (for monoclonal G.K). On the -HR3» program, the sensitivity of detection was 1.5 • 2.0 mg/dL (for albumin and Bence Jones protein).
Approximately the same staining sensitivity/intensity was observed when the electrophoresis was performed on neat serum followed by staining with
amido black vs. electrophoresis of a serum diluted t.^4 followed by staining with acid violet.
NOTE Accoraing to the position of the monoclonal component and polyclonal background in the gamma zone, the detection limit may vary.
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Sebia Bence Jones Immunofixation Procedure
PROCEDURE
The HYDRASYS system is a semi-automated multi-parameter instrument. The automated steps include processing of HYDRAGEL agarose gels in
the following sequence sample application, electrophoretic migration, incubation with fixative solution and antisera, drying, staining, destaining and
linal drying. The manual steps include handling samples and gels, application of fixative and antisera and setting up the instrument for operation.
READ CAREFULLY HYDRASYS INSTRUCTION MANUAL
I.

MIGRATION SET UP
1 Switch on HYDRASYS instrument
2 Place one applicator for HYDRAGEL 1 BENCE JONES or HYDRAGEL BENCE JONES 2.'4 (2 samples), two applicators for HYDRAGEL
BENCE JONES 2.'4 (4 samples) or three applicators for HYDRAGEL 9 BENCE JONES, on a flat surface with the well numbers in the rightside-up position (Fig 1).
• Apply to pL sample m each well. Load each applicator within 2 minutes.
MIGRATION / IMMUNOFIXATION TRACK
WELLS NO :

HYDRAQ£L LBENCLJONES

ELP

GAM

K

L

Kf

Lf

1

2

3

4

5

6

HYDRAGEL BENCE JQN£S 2.4
SAMPLE N“ 1 OR 3

2

3

4

5

6

SAMPLE N'^^ 2 OR 4

9

10

11

12

13

7
14

2
8
14

3
9

4
10

5
11

6
12

15

16

17

18

HYDRAGEL9 BENCE JONES
SAMPLE N" 1,4 OR 7

1

SAMPLE N“2, 5 OR 8

7

SAMPLE N' 3, 6 OR 9

13

NOTE: For HYDRAGEL BENCE JONES 2/4. the wells r\o. I, 8 arxi 15 are nor used m this test, they may be marked with a felt tip pen to
avoid filling them with sample by mistake
- Place the applicator(s) into the wet storage chamber with the teeth up [handle it (them) by the plastic tooth protection frame].
- Let the samples diffuse into the teeth for 5 minutes after the last sample application.
See wet chamber package insert lor further details.
3

Open the lid of the Migration Module and raise the electrode and applicator carriers.

4

Select "1 BJ SM..DM' migration program for HYDRAGEL 1 BENCE JONES, "2/4 BJ-UP SM DM' for HYDRAGEL BENCE JONES 2.'4 or
*9 BJ SM " (or HYDRAGEL 9 BENCE JONES, from the instrument menu (left side of the keyboard).
Remove buffered strips from the package ; handle them by the plastic ends. Engage the punched ends of the strip's plastic backing to the pms
on the electrode earner: the strip's plastic backing must face the carrier (Fig. 2).
Unpack the HYDRAGEL plate
• Roll quickly and uniformly one thin filter paper onto the gel surface to absorb the excess of liquid. Remove the paper immediately.
WARNING: Do not leave the filter paper tor a too long contact with the gel to avoid Its dehydration.

WARNING: Never close the lid while the carriers are raised !

5
6

Pool 120 pL distilled or deionized water for HYDRAGEL 1 BENCE JONES or 200 pL for HYDRAGEL BENCE JONES 2'4 and HYDRAGEL
9 BENCE JONES, on the lower third of the frame printed on the temperature control plate of the migration module
- Place the gel plate (the gel side up) with its edge against the stop at the bottom of the printed frame (Fig 3).
- Bend the gel and ease it down onto the water pool (Fig. 3). Ensure that no air bubbles are trapped, water is spread underneath the entire
gel plate and the gel is lined up with the printed frame,
Lower both earners down. In this position the buffered strips do not touch the gel. DO NOT FORCE THE CARRIERS ALL THE WAY DOWN
Remove the appiicator(s) from the wet chamber Handle it (them) by the protection frame.
Snap off the applicator teeth’s protection frame
- Place the applicator(s) on the carrier ;
• With HYDRAGEL 1 BENCE JONES or HYDRAGEL BENCE JONES 24 (2 samolesl. into position No 6,
■

7.
8

• With. HYDRAGEL BENCE JQN£S 2.'4 14

samolfisl. into position No 3 and 9,

- With HYDRAGEL 9 BENCE JONES, into position No 2. 6 and 10.
To improve reproducibility of sample application, always position the applicators on the left side of the carrier.
IMPORTANT: The numbers printed on the applicator(s) must face the operator (Fig. 4),
9 Make sure the earners are lowered. Close the lid of the migration module.
10 Start the procedure immediately by pressing the green arrow -START- key on the left Side of the keyboard.
IMPORTANT: Make sure that the ventilation air inlet on the right side of the instrument is not blocked.
MIGRATION - DESCRIPTION OF THE AUTOMATED STEPS
• The two earners are lowered so that buffered strips and applicator(s) contact the gel surface.
• Sample applicator earner rises up,
• Migration is carried out under 10 W constant for HYDRAGEL 1 BENCE JONES and under 20 W constant tor HYDRAGEL BENCE JONES 2/4, until
42 Vh accumulated (for about 9 minutes) and under 20 W constant until 31 Vh accumulated (for about 7 minutes) for HYDRAGEL 9 BENCE JONES,
at 20 "C controlled by Peltier effect
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The electrode carrier rises to disconnect the electrodes.
An audible beep signals that the migration module lid unlocks. The following message is displayed on the screen ;
NOTE. The migration module lid remains locked during all migration steps.

• ^

AS»

II. IMMUNOFIXATION SET UP
1. Open the migration module lid.
2. Remove the sample applicator(s) and discard
3. Raise both carriers, remove the buffered strips by their plastic ends and discard.
■ Remove both earners.
- Wipe electrodes with soft wet tissue.
- Leave the gel in place in the migration module.
4. Set up the reagent application template as follows (Fig. 5);
- Position the application template guide on the lower two anchoring pins (the guide may stay in the migration module all the time).
- Hold the template by the flap and insert it onto the guide (the right dip on the notch).
- Lower the template onto the gel.
■ Adjust the template position lor perfect alignment between electrophoretic profiles and wells of the template (see accessory kit for
HYDRASYS 9 BENCE JONES SEBIA. PN 1266, for instructions).
5. Apply reagents as follows.
VOLUME (pL)
TROUGH
ELP
GAM
K
L
Kf
Lf

Template
1, 2 & 4 BJ
40
25
25
25
25
25

Template
9 BJ
20
15
15
15
15
15

REAGENT
fixative solution
trivalent antiserum
anti-kappa light chain (free & bound) antiserum
anti-lambda light chain (free & bound) antiserum
anti-kappa free light chain antiserum
anti-lambda free light chain antiserum

COLOR
yellow
violet
green
blue
orange
red

NOTE: To avoid a mix-up, reagent colors are shown both on the vial labels and the application template wells.
HYDRAGEL 9 BENCE JONES : It is recommended to apply the antisera in the following order: lambda free, kappa tree, lambda, kappa and
GAM, and at last, fixative solution.
■ Take reagents without trapping any air bubbles in the pipette tip.
- Apply the reagents (Fig. 6):
- Mold pipette vertically and rest its tip lightly at the bottom of the well
- Inject reagent so It spreads through the trough without trapping any bubbles.
Close the lid of the migration module.
Start the procedure immediately by pressing the green arrow -START- key on the left side of the keyboard. A message -[INCUBATION]appears on the screen.
IMMUNOFIXATION - DESCRIPTION OF THE AUTOMATED STEPS
• Incubation at 20 X tor 10 minutes (controlled by Peltier effect).
• An audible beep signals that the migration module lid unlocks. The following message is displayed on the screen: - {> AS (SM)».
NOTE: The migration module lid remains locked dunng incubation.
III. REMOVAL OF THE EXCESS OF REAGENTS
1 Open the migration module lid.
2. Remove the excess of reagents with the filter paper combs : one comb lor the 1 BENCE JONES and 2 BENCE JONES templates, two combs
for the 4 BENCE JONES template and three combs for the 9 BENCE JONES template (Fig. 7) ;
- Insert the comb(s) at a 30 ° angle into the slots at the lower end of the template troughs so that the teeth touch the vertical side away from
the operator.
Allow the teeth to contact delicately the liquid by tilting the comb(s) to a 45 ^ angle enabling the teeth to wick off the liquid (Fig 8).
IMPORTANT: The teeth must not contact the gel. Each comb must stay inclined (45 “). If it is straight up, it could damage the gel.
3 Start the procedure by pressing the -START« key (green arrow on the left side of the keyboard)
REAGENT REMOVAL - DESCRIPTION OF THE AUTOMATED STEPS
• The reagents are allowed to wick off the troughs for 15 seconds at 20 X (controlled by Peltier effect).
• An audible beep rings. The following message is displayed on the screen ; - 0 PAP.».
IV. BLOTTING OF THE GEL
1
Remove the comb(s)
2. Check that the reagents are well absorbed as indicated by
• the absence of reagents on the gel.
- the full length of the teeth are stained.
If the reagent absorption is incomplete, insert the same fitter paper comb again (in the same position) and repeat manually the removal
procedure.
3. Grasp the reagent application template by the flap, lift it and remove it.
4 Apiply a thick filter p>aper on the gel:
■ incline the filter papier at a 45 * angle and line up its edge with the gel edge
- ease it down onto the gel.
IMPORTANT: Press firmly on the whole surface of the filter paper to ensure perfect adherence on the gel.
5. Close the lid of the migration module.
6. Start the procedure by pressing the -START- key (green anow on the left side of fhe keyboard).
7. Clean the application template with a small brush (e.g.. toothbrush). DO NOT USE ALCOHOL OR SOLVENTS. Ensure the template is
completely dry before re-use ; remove water dropilets from the wells by tapiping it on soft piapier.
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Sebia Bence Jones Immunofixation Performance Data
Reproducibility
Cels

-

to

•

Gel

Four urine samples containing non-polymerized. either lambda or kappa, Bence Jones light chain were each run on 10 gels from the same lot using
the standard procedure and HYDRAGEL 4 BENCE JONES kit.

Lot

-

to

-

Lot

Two urine samples containing non-polymerized, either kappa or lambda, Bence Jones light chain were used. Each sample was applied in all (24) tracks
of two HYDRAGEL 4 BENCE JONES gels. One gel of the two was immunofixed with appropriate anti free & bound light chain antiserum and the other
gel with anti free light chain antiserum. Gels from three different lots were used this way with each sample.
Results. The Bence Jones proteins were correctly identified in each sample and on all gels, there wore no false positives and no differences were
observed among the repetitions.

Accuracy • Detection and Identification of Bence Jones Proteins
Thirty six urine and ten serum samples, pathological and normal, were analyzed using the HYDRAGEL 4 BENCE JONES kit and a similar,
commercially available immunofixation procedure. The results of the two immunofixation procedures were in perfect agreement with each other and
with the results and diagnosis provided by a hospital

Sebia Capillarys Urine Immunotvping Procedure
The CAPILLARYS System is a multipaiamelei instrument for unnary proteins analysis on 6 parallel capillaries in ttie CAPILLARYS IMMUNOTYPING
URINE procedure, m the following sequence
■ Bar code reading ol the sample-rack and ot the urine sample lube
■ Sample dilution ,
• Mixmg diluted urine samples with ELP solution / specific antisera .
■ Capillary washing ;
■ Injection of dilutiKf samples .
■ Protein separation and direct detection ol the separated proteins on capillaries
The manual steps include
■ Placement ol microtubes (without caps) containing the samples to analyze on holding nemolysing tubes in sample-racks, each tube bemg identified
with the specific sample identificalion bar code label corresponding to the sample to analyze.
• Placement ol one opened antisera segment in each sample-rack ,
• Placemertt of racks on the CAPILLARYS instrument ,
• Removal ol sample-racks after analysis
Electrophoretic analysis on CAPILLARYS System using CAPILLARYS URINE procedure has to be first pertonned to select samples suspected to
contain monoclonal protein(s) (e g . with abnormal protein pattern or traction)
PLEASE CAREFULLY READ THE CAPILLARYS INSTRUCTION MANUAL
I.

PREPARATION OF ELECTROPHORETIC ANALYSIS
1 Select sarr^les with abnormal protein fraction on the electrophoregrams obtained with CAPILLARYS URiNE procedure.
2 Switch on CAPILLARYS instrument and computer
J. Set up the software, validate and the instrument automatically starts Alter 10 minutes, the CAPILLARYS System is ready to use.
4 For each sample to analyze, determine the "Ratio unne' value of fhe abnormal traction to characterize from the electrophoretic pattern obtained
with the "URINE" analysis program (see the paragraph 'Result analysis" of the CAPILLARYS URINE kit package insert) The "Ratio urine" is
defined by the proportion of the abnormal fraction area related to the Normal Control Serum proteins total area
5 Select the dilution program to apply automatically according to the 'Ratio unne" value:
• “ HYPOGAMMA" if the * Ratio urine " value is < 0.55,
• ■ STANDARD ” if the " Ratio unne * value is comprised between 0 55 and 1 55.
• " HYPERGAMMA" if the" Ratio unne ” value is > 1.55
NOTE: When the “Ratio unne’value is ± 10% from one of the threshold value (0.55 ot 1.5S). it is recommended to select the dilution program
according to the abnormal traction to characterize with the CAPILLARYS IMMUNOTYPING URINE procedure
■ to improve the detection of a weak traction, dilute less the unne sample by selecting the ' HYPOGAMMA “ dilution program instead ol
“ STANDARD ’ program and * STANDARD * ehMion program instead Ol' HYPERGAMMA * program,
■ to improve the mmunotypmg ol a high fraction, dilute more the unne sample by selecting the ‘ STANDARD ' dilution program instead ol
" HYPOGAMMA " program and " HYPOGAMMA ’ dilution program instead of ’ STANDARD “ program
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6.

For unr>e samples analysis, the CAPILLARYS IMMUNOTYPING kii is intended to run with "IMMUNOTYPING URINE" analysis program from
the CAPILLARYS instrument and CAPILLARYS PROTEIN(E) 6 butler To select ’ IMMUNOTYPING URINE* analysis program and place the
CAPILLARYS PROTEIN(E) 6 butter vial in the instrument, please read caretully the CAPILLARYS instruction manual.

NOTE: rt IS not n«c»ssary to change the buffer vial when sv/itchrng from CAPILLARYS URINE procedure to CAPILLARYS IMMUNOTYPING
URINE procedure (and vice versa).
7

Place one empty hemolysmg tube (used as holder) in position No 1 on each sample rack, and then, the microtube containing the dialyzed
urine sample Cut the cap ol each microtube before using it.
Keep the cap ol each microtube lor lurther storage of samples, if necessary

6

IMPORTANT: It is recommended to identity each hemolysmg lube holding the microtube which contains sample to analyze, with the specilic
sample ideniitication bar code label corresponding to the sample.
9

The bar code ol each tube must be visible in the openings of the sample rack
II the unnc sample placed on the sample rack is not previously selected, the ’ H YPOGAMMA * dilution program will automatically be performed.
to For each sample to analyze, take a new antisera segment, remove its cover and place it on the same sample rack than that of the hemoiysing
tube and microtube containing the sample A message will be displayed if the segment is missing

NOTE: The antisera segments are shaped m order to fit on sample racks of the CAPILLARYS System
11

Slide the sample earner with the sample tube and the antisera segment mto the CAPILLARYS System through Ihe opening in the middle of
the instrument. Up to 13 sample racks can be introduced successively and continuously into Ihe system
12 Remove analyzed sample racks from the plate on the leh side of the instrument
13 Take oil carefully used antisera segments from each sample rack and discard them

WARNING: The used antisera segments have to be handled as biological hazards.

Sebia Capillarvs Urine Immunotvping Performance Data
PERFORMANCE DATA
Reproducibility within run
Bupiixi icibiliiy within run war. demonstiated on live d herent pstnciog.cn sampins cont.iining one oi two rmiryickiiial components ano on one nrirmai
sample Lacn snmpie was anaiy/od 6 times n trw same lu"' witti CAPILLARYS IMMUNOTYPING URINE procedure and "HYPOGAMMA" dilution
program vuih 2 d herent lots ol reaqet'ts lor anliSO'a segments cacn .ycgmenl cor lainiiig the same reagent in every well according to the tested sample
(EIP solution and anti ki G. ant. Ig A ant. kj W anti Kappa oi ant. i..inibda antisera)
All repeats gave concordant results witho run and wilh.n ttie two ms ot leagents cor,lamed n Ihe antisera soginerits Padonis correspondeo to the
type of each tested samp.e

Reproducibility between runs <ind lot-to-lot
Rcproil-.iCibility U'tween runs was dr.monstralod on seven ii.i1o'en; pathological sanipios with monoclor.a; or tiicloiiai components arc on one normal
sample, eic'lirt ng diMerenl prole n coiiCBnll.Jtion.s Foui samples (with a tatm untie < 0 bf>i wor* analyzed will' CAPIll ARYS IMMUNOTYPING URINE
procedure ano "tlYPOGAMMA' dilution piogiam, 2 s.vi’ples iw th i latio urine ctiinprised belwmrn 0,53 and 1 5b) with ■S’‘AN0AR0" d lution program
and 2 sanipes (wir a ratio o'lnc > i 55) witn HYPERGAMMA’ dilution oroqram These samples we'e analyzed A limes using 3 lots Ol antisera
scgitif'its
All 'epeaL, g.i.e co’icot<Unl results behvee i runs and ict-to iot Patterns co'rectly idenidied the rnonoclonal components
The analysis nl the nomi.il sample showed a prilyclonal pattern wittviul any abnormal component

Concordance Study
Concorda:-ce sludv 'Pt paraproteins and iroe light chains cha':icieriz,iiioFi was perlormuo on 33 ditterent pathological urme samples (with paraprotens
01 Kaf'.pH or lambd.j t-ee light ctiams). on 22 samples w in |iol>clonal pattern and on 6 normal samples txitween CAPILLARYS IMMUNOTYPING
URINE procedure and imrnunotixation nri agarose gels. HYORAGEL 9 BE.NCt' JONES SEBIA iretB'ence proceduie) All 6t samples have been run
on tKith techniques
’’his study demonstrated a 100 “c agreoment belwcon the ? Iccnniqucs
‘^or ihe 6 normal urine samples comptole agreement (concordance'
For itie 22 urme samples with polyclonal p.ittem complete agieeineiit iconcofda'ire)
EOT the 33 pathological unne samp'es complete agreement (concordance!
For the anaNzeo pathological unne s.impics. the results obiained w th the injividudl procedures wore m agreement a'xl tdeniical bat'ds were deiecled
on .ill oathclogical sampies with each system

Sensitivity
Serial dlutions were prepared with typeal urine samples exhibiting Bence Jones proteins and were analyzed with CAPILLARYS IMMUNOTYPING
URINE le< hiiique Tne minimal detection am t for free light chains was about 2 5 mg/dL w.th me analyzed unne samples and with anti Kapp.i and antiLamtxla antisera contained r the CAPll.LAHYS IMMUNOTYPING kil
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Appendix C

Result Tables

Table 3(a): Urine Protein Electrophoresis Interpretations and BJP Screen Results
SAxMPLE
NO.
001
002
003
004
009
010
013
015
016
017
018
019
020
021
023
025
026
027
029
030
031
033
035
036
038
039
040
041
042
043
044
046
047
048
051
052
053
055
056
057
058
059
060
061
062

15 Bl- B2
AG
AG
AG
GPR
GPR
ABG
AP
GPR
AAAB
ABG
GPR
AB
ABG
AP
GPR
AP
ABG
AG
AP
AG
AG
AA
AG
AG
AAAB
AB
AAAB
GPR
AP
AAB
AAAB
GPR
GPR
ABG
ABG
AAAB
GPR
AP
AG
AG
AB
AAAB
AP
AAAB
AAB

Capillarys
AG
AG
AG
GPR
GPR
GPR
AAB
ABE
GPR
GPR
GPR
AAB
GPR
AAB
GPR
ABE
GPR
AG
GPR
AG
AG
AA
AG
AG
AAAB
AAB
AAB
GPR
AAAB
AAB
GPR
GPR
AAB
GPR
GPR
AAB
GPR
AP
AG
AG
AB
AAAB
AAB
AAAB
GPR

HR Cone.
AG
AG
AG
AG
GPR
GPR
AAAB
GPR
GPR
ABG
GPR
AAAB
GPR
AB
GPR
AP
GPR
AG
AP
AG
AG
AAAB
AG
AG
AAAB
AAB
AAAB
GPR
AAAB
AAAB
GPR
GPR
GPR
ABG
ABG
GPR
GPR
AP
AG
AG
AB
AAAB
AP
AAAB
GPR
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HR Neat
AG
AG
AG
AG
GPR
ABG
AP
AAB
AAB
ABG
GPR
AP
ABG
AP
GPR
AP
GPR
AG
AP
AG
AG
AP
AG
AG
AAAB
AB
AP
GPR
AP
AAB
AP
GPR
AAB
ABG
ABG
AB
GPR
AP
AG
AG
AP
AB
AP
AP
GPR

Urine
Protein g/L
0.58
0.49
0.21
1.35
1.88
1.52
0.19
1.17
0.59
4.34
1.23
0.18
2.55
0.29
4.78
0.27
3.87
0.79
0.2
0.62
1.9
0.27
0.3
0.21
0.94
1.92
0.19
2.57
0.18
1.31
0.6
3.21
1.39
1.59
2.31
0.28
1.46
0.5
0.15
5.06
0.18
0.41
0.15
0.35
1.45

BJP IFE
Screen
POS
POS
POS
POS
Neg
Neg
Neg
Neg
Neg
POS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
POS
Neg
POS
POS
Neg
POS
POS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
POS
Neg
Neg
Neg
Neg
Neg
POS
POS
POS
Neg
Neg
Neg
Neg
Neg

K/k

Table 3 (b): Urine Protein Electrophoresis Interpretations and BJP Screen Results
SAMPLE
NO.
065
066
068
069
070
072
073
076
077
078
079
080
081
084
086
087
088
089
090
091
092
096
097
098
100
101
103
105
108
109
113
115
116
117
118
119
120
121
122
123
124
125
126

15 01-152
GPR
GPR
AAAB
AAAB
AB
GPR
AP
AP
AG
AG
GPR
ABG
AAAB
AAAB
AAB
GPR
AAAB
GPR
AB
AG
AG
AB
AB
GPR
AB
GPR
AP
GPR
AAB
AB
AAB
AP
AAB
AAB
AAB
AG
AP
GPR
AAAB
AP
AB
AG
GPR

Capillarys
GPR
AAB
AAAB
GPR
AAB
GPR
AAAB
AAAB
AG
AG
GPR
ABG
AAB
AAB
GPR
GPR
GPR
GPR
AAAB
AG
AG
AAAB
GPR
GPR
AAB
GPR
AAB
GPR
AAAB
GPR
AAAB
AAB
AAB
AAAB
GPR
AG
AA
AAB
GPR
AP
AAB
AG
GPR

HR Cone.
GPR
GPR
GPR
AAAB
AB
GPR
AP
AG
AG
AG
GPR
ABG
GPR
AAAB
GPR
GPR
GPR
GPR
AAAB
AG
AG
AAB
AAB
GPR
AAAB
GPR
AB
GPR
GPR
ABG
GPR
AB
AAB
AAAB
GPR
AG
AP
GPR
AAAB
AP
AAB
AG
GPR
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HR Neat
GPR
AAB
GPR
AP
AB
GPR
AP
AP
AG
AG
GPR
AB
AAB
AB
AB
AAB
AB
GPR
AP
AG
AG
AB
AB
AAAB
AP
GPR
AP
GPR
AAB
AP
AP
AP
AP
AAB
AAB
AG
AP
AAB
AAAB
AP
AB
AG
GPR

Urine
Protein (g/L)
10.74
1.12
2.68
0.32
0.34
1.11
0.51
0.22
0.35
0.15
1.36
0.28
0.66
1.16
0.67
0.56
0.44
3.81
0.25
1.8
1.33
0.18
0.36
0.74
0.15
1.94
0.16
1.58
1.31
0.43
0.35
0.21
0.18
1.69
2.29
1.22
0.18
1.03
0.64
0.22
0.27
0.27
2.96

k/X BJP
IFE Screen
Neg
Neg
Neg
Neg
Neg
Neg
Neg
POS
POS
POS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
POS
POS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
POS
Neg
Neg
Neg
Neg
Neg
POS
Neg

Table 4: Monoclonal Peak Quantifications as determined by Densitometry or
Phoresis (Capillarys Only)

Sample I.D.
UPEOOl
UPE002
UPE003
UPE004
UPE017
UPE027
UPE030
UPE031
UPE035
UPE036
UPE046
UPE055
UPE056
UPE057
UPE076
UPE077
UPE078
UPE091
UPE092
UPE119
UPE125

Monoclonal Peak Quantification (%)
Capillarys
Hydragel 151Hydragel HR
152
Urine
Cone.
43.4
75.8
77.1
42
53.9
53.5
1.3
22.2
19.7
ND
ND
ND
ND
ND
ND
39.2
12.4
10.7
56.3
68.8
68
71.1
83.1
86.1
12.7
23.8
27.2
11.4
30
28.5
ND
ND
ND
ND
ND
ND
3.6
14.8
17.6
59.5
66.9
66.3
ND
7.8
ND
54.9
75.3
77.6
19.4
68.5
72.9
13.3
27.5
23.6
65.9
79
74.5
3
5.2
5.6
51
76.7
76.9

Hydragel HR
Neat
69.3
50.3
19.2
ND
ND
21.2
77
89.2
42.9
33.7
ND
ND
26.8
70.9
ND
91.8
56.2
41.7
85.7
3.2
72.2

ND = Monoclonal Peak not detected / not strong enough to quantify
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Table 5: Bence Jones Protein Classification by Immunofixation and Immunotyping
Sample I.D.

Bence Jones Immunofixation

Urine Immunotyping

001

Free k + IgG/A/M

k

Biclonal

k

*

002

Free

k

Biclonal

k

*

003

Free k

Monoclonal k*

004

Weak free X

Negative

017

Free k (co-incident with P globulins)

Negative

027

Free k

Monoclonal k*

030

Free I + IgG/A/M X

Monoclonal X*

031

Free k + IgG/A/M

Biclonal

035

IgG/A/M K

Monoclonal k* (No IgG/A/M rxn)

036

Free X

Monoclonal X*

046

Weak free X

Negative

055

Weak free k

Negative

056

Free k

Monoclonal k*

057

Free X

Monoclonal X*

076

IgG/A/M X

Negative

077

Free

k

Monoclonal k*

078

Free

k

Monoclonal k*

091

Free

k

092

Free X

Monoclonal X*

119

IgG/A/M X

IgGX

125

Free

Monoclonal k*

k

+ IgG/A/M

k

+ IgG/A/M k

k

*

Monoclonal k* + IgG

k

k

* Denotes requirement for further immunofixation with Free Light Chain antisera as these are
not part of the Immunotyping screen.
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Appendix D

Statistical Manipulation

Urine Protein Electrophoresis Comparison

Hydragel Blp2 v*s Capillarys Urine

15 K1- &2 * Capillarys Crosstabulation
Capillarys
15
B1112

Glomerular

Tubular

Mixed

Count
Expected Count

Overflow

Total

Count
Expected Count
% within Capillarys
Count
Expected Count
% within Capillarys

Glomerular
5
2.0
83.3%
0
1.5
.0%
1

Tubular
16
11.3
48.5%
14

3
7.5

1.4
16.7%
0
1.1

9.1%
0
6.0

% within Capillarys
Count

.0%
6

.0%
33

6.0
100.0%

% within Capillarys

9
11.3
27.3%
8
8.3
24.2%
16
7.5

8.3
42.4%

% within Capillarys
Count
Expected Count

Expected Count

Mixed

Overflow
0
5.5
.0%
0
4.0
.0%
0
3.6

33.0

48.5%
0
6.0
.0%
33
33.0

.0%
16
2.9
100.0%
16
16.0

100.0%

100.0%

100.0%

Chi-Square Tests

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
109.760®
103.188
45.879

9
9

Asymp. Sig.
(2-sided)
.000
.000

1

.000

df

88

3- 7 cells (43.8%) have expected count less than 5. The
minimum expected count is 1.09.
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Total
30
30.0
34.1%
22
22.0
25.0%
20
20.0
22.7%
16
16.0
18.2%
88
88.0
100.0%

Symmetric Measures

Nominal by Nominal
Measure of Agreement
N of Valid Cases

Asymp.
Std. Erroi^

Value
1.117
.645
.450
88

Phi
Cramer's V
Kappa

Approx,

8.094

.066

Approx. Sig.
.000
.000
.000

3- Not assuming the null hypothesis.
b- Using the asymptotic standard error assuming the null hypothesis.

Hydragel Blp2 v^s Hydragel HR Neat

15 R1- B2 * HR Neat Crosstabulation

15
1^1'

Glomerular

Count
Expected Count
% within HR Neat
Count
Expected Count
% within HR Neat
Count

Tubular

Mixed

Expected Count
% within HR Neat
Overflow

Count
Expected Count
% within HR Neat

Total

Count
Expected Count
% within HR Neat

Glomerular
29
14.0
70.7%

HR Neat
Tubular
Mixed
1
0
5.5
4.8

12
10.3
29.3%

.0%
8
3.5
57.1%

0
9.3

6
3.2

.0%
0

42.9%
0

7.5
.0%
41

2.5
.0%
14

41.0

14.0
100.0%

100.0%

6.3%
2
4.0
12.5%
13
3.6

Overflow
0
5.8
.0%
0
4.3
.0%
1
3.9
5.9%

81.3%
0
2.9

16
3.1
94.1%
17

.0%
16
16.0
100.0%

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

70.908
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16
16.0
18.2%

100.0%

1

.000

3- 10 cells (62.5%) have expected count less than 5. The
minimum expected count is 2.55.

25.0%
20
20.0
22.7%

100.0%

9
9

88

22
22.0

88
88.0

Asymp. Sig.
(2-sided)
.000
.000

df

30
30.0
34.1%

17.0

Chi-Square Tests

Value
146.559^
143.820

Total

Symmetric Measures

Nominal by Nominal

Value
1.291

Phi

Measure of Agreement

Cramer's V

.745

Kappa

.655

N of Valid Cases

Asymp.
Std. Erroi^

Approx, 'f

.062

10.614

Approx. Sig.
.000
.000
.000
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a- Not assuming the null hypothesis.
b- Using the asymptotic standard error assuming the null hypothesis.

Hydragel Blp2 v’s Hydragel HR Cone.

15 R1- R2 * HR Cone Crosstabulation

15
lilS2

Glomerular

Expected Count
Tubular

Mixed

Overflow

Total

Count
% within HR Cone
Count
Expected Count
% within HR Cone
Count
Expected Count
% within HR Cone
Count
Expected Count
% within HR Cone
Count
Expected Count
% within HR Cone

Glomerular
17
5.8
100.0%
0
4.3
.0%
0

HR Cone
Tubular
Mixed
9
3
6.8
11.3
45.0%
9.1%
11
11
5.0
8.3
55.0%
33.3%
0

3.9
.0%

Total
30
30.0
34.1%

6.1
5.6%
0
4.5
.0%
1

22
22.0
25.0%
20

4.1

20.0
22.7%

4.5
.0%
0

57.6%
0

5.6%
16

3.6
.0%

6.0
.0%

3.3
88.9%

16
16.0
18.2%

20
20.0

33
33.0

18
18.0

88
88.0

100.0%

100.0%

100.0%

100.0%

0
3.1
.0%
17
17.0
100.0%

19
7.5

Overflow
1

Chi-Square Tests

Pearson Chi-Square

9

Asymp. Sig.
(2-sided)
.000

136.990

9

.000

61.988

1

.000

Value
140.176®

Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

88

df

a- 8 cells (50.0%) have expected count less than 5. The
minimum expected count is 3.09.
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Symmetric Measures

Nominal by
Nominal

Value
1.262
.729
88

Phi
Cramer's V

N of Valid Cases

Approx. Sig.
.000
.000

Not assuming the null nypotnesis.
Using the asymptotic standard error assuming the null
hypothesis.

Symmetric Measures

Measure of Agreement
N of Valid Cases

Kappa

Value
.624
88

Asymp.
Std. Error®
.062

a- Not assuming the null hypothesis.
b- Using the asymptotic standard error assuming the null hypothesis.
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Approx.
10.493

Approx. Sig.
.000

Peak Quantification Comparison
Descriptives

15B1-(J2

Statistic
43.5278

Mean
95% Confidence
Interval for Mean

Lower Bound
Upper Bound

Std. Error
7.28059

28.1671
58.8885

5% Trimmed Mean

43.7475

Median

41.7500

Variance

954.126

Std. Deviation

30.88892

Minimum

.00

Maximum

83.10

Range

83.10

Interquartile Range

61.22

Skewness
Kurtosis
HR Cone

Mean
95% Confidence
Interval for Mean

Lower Bound
Upper Bound

-.101

.536

-1.783

1.038

44.4222

7.14177

29.3544
59.4900

5% Trimmed Mean

44.2636

Median

41.2000

Variance

918.088

Std. Deviation

30.29996

Minimum

5.60

Maximum

86.10

Range

80.50

Interquartile Range

59.22

Skewness
Kurtosis
Capillarys

Mean
95% Confidence
Interval for Mean

Lower Bound
Upper Bound

-.010

.536

-1.885

1.038

31.2167

5.82321

18.9308
43.5026

5% Trimmed Mean

30.6630

Median

29.3000

Variance

610.377

Std. Deviation

24.70580

Minimum

1.30

Maximum

71.10

Range

69.80

Interquartile Range

45.80

Skewness
Kurtosis
HR Neat

Mean
95% Confidence
Interval for Mean

Lower Bound
Upper Bound

.195

.536

-1.636

1.038

47.2944

7.31813

31.8545
62.7343

5% Trimmed Mean

47.4494

Median

46.6000

Variance

963.990

Std. Deviation

31.04819

Minimum

.00

Maximum

91.80

Range

91.80

Interquartile Range

52.70

Skewness
Kurtosis

94

-.142

.536

-1.269

1.038

Tests of Normality
Kolmogorov-Smirnov^
15 111- (12
HR Cone
Capillarys
HR Neat

Statistic
.220
.209
.210
.150

df
18
18
18
18

Sig.
.022
.036
.034
.200*

Statistic
.868
.852
.886
.936

Shapiro-Wilk
df
18
18
18
18

Sig.
.017

*• This is a lower bound of the true significance.
3- Lilliefors Significance Correction

Hydragel plp2 Histogram

Histogram

Mean •>43.53D
Std. Dev =30 8890
N =18

95

.009
.032
.244

Hydragel HR Cone. Histogram

Histogram

Mean =44.42C
Std, Dev. =30.30C
N =18
20.00

40.00

60.00

HR Cone

Capillary’S Urine Histogram

Histogram

Mean -31.220
Std. Dev. =24.7060
N -18
20.00

40.00

Capillarys
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Hydragel HR Neat Histogram

Histogram

20.00

40.00

60.00

HR Neat

97
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Non-Parametric Wilcoxon Signed Ranks Test
Ranks
N
HR Cone -15 SI-S2

Negative Ranks

73

Mean Rank
9.14

Sum of Ranks
64.00

Positive Ranks

11b

9.73

107.00

Ties
Capillarys -15 SI-S2

0^

Total

18

Negative Ranks

15^^

9.77

146.50

Positive Ranks

3®

8.17

24.50

Ties

0^

Total
HR Neat -15 SI-S2

18

Negative Ranks

69

5.50

33.00

Positive Ranks

10^

10.30

103.00

Ties
Capillarys - HR Cone

2'

Total

18

Negative Ranks

16i

9.50

152.00

Positive Ranks

2k

9.50

19.00

Ties

O'

Total
HR Neat - HR Cone

18

Negative Ranks
Positive Ranks
Ties

7.13

57.00

lO""

11.40

114.00

0°

Total
HR Neat - Capillarys

8m

18

Negative Ranks
Positive Ranks
Ties

3P

4.67

14.00

159

10.47

157.00

0^

Total

18

a. HR Cone < 15 (i1-(J2
b. HRConc> 15(i1-(J2
c. HR Cone = 15 fJ1-fl2
d- Capillarys < 15 SI - (J2
e. Capillarys > 15 SI - S2
Capillarys = 15 SI - S2
g- HR Neat < 15S1-S2
h. HR Neat> 15 SI- S2
i- HR Neat= 15 S1-S2
i- Capillarys < HR Cone
k- Capillarys > HR Cone
•• Capillarys = HR Cone
m. HR Neat < HR Cone
n. HR Neat > HR Cone
0. HR Neat = HR Cone
P- HR Neat < Capillarys
Q- HR Neat > Capillarys
HR Neat = Capillarys
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Test Statistic^
HR Cone - Capillarys - HR Neat - Capillarys - HR Neat - HR Neat 15
(12 15 (11- (12 15 (11- Q>2 HR Cone HR Cone Capillarys
-1.241^
z
-3.1143
-.936®
-2.657^
-1.810^
-2.896^^
Asymp. Sig. (2-taile(
.004
.214
.002
.008
.070
.349
3- Based on negative ranks,
b- Based on positive ranks.
C- Wilcoxon Signed Ranks Test

99

